{
  "CRC": [
    {
      "Disease Setting": "Peri-operative ",
      "Trial Name": "GSK219606 (AZUR2)",
      "Full title": "A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer.",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Trial Intervention/Arms": "A: Dostarlimab x 4, OR, Dostarlimab x 4 \nB: OR, SOC (CAPEOX, FOLFOX)",
      "Eligibility ": "Inclusion criteria:\nUntreated resectable CRC.\nMSI-H/dMMR. \nT4N0 or stage III only.\nExclusion criteria:\nHas received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of the current diagnosis of colon cancer.\nPatients with a history of colonic obstruction in the context of current colon cancer diagnosis and treated with colonic stents.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT05855200",
      "Study status": "Active",
      "Schema image": "NCT05855200.png"
    },
    {
      "Disease Setting": "1st line ",
      "Trial Name": "61186372COR3001 (ORIGAMI-2)",
      "Full title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer.",
      "Additional notes": null,
      "Tissue Requirements": "Fresh tumor tissue: KRAS, NRAS, and BRAF wild-type (WT) tumor by local and/or central testing (if available).",
      "Trial Intervention/Arms": "A: Amivantamab + chemo (mFOLFOX6 or FOLFIRI)\nB: Cetuximab + chemo (mFOLFOX6 or FOLFIRI)",
      "Eligibility ": "Inclusion criteria:\nUnresectable left-sided CRC.\nKRAS/NRA/BRAF WT. \nNeoadjuvant/Adj in non-metastatic disease eligible (>12m after last dose).\nExclusion criteria:\nHas a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatmens\nKnown mismatch repair deficiency (dMMR/MSI-H) status and HER2-positive/amplified tumor.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06662786",
      "Study status": "Active",
      "Schema image": "NCT06662786.png"
    },
    {
      "Disease Setting": "1st line ",
      "Trial Name": "D798VC00001 (CANTOR)",
      "Full title": "A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR).",
      "Additional notes": null,
      "Tissue Requirements": "FFPE tumor sample collected as per SoC.",
      "Trial Intervention/Arms": "A: Volrustomig + FOLFIRI + Bevacizumab\nB: FOLFIRI + Bevacizumab ",
      "Eligibility ": "Inclusion criteria:\nNo radiological evidence of liver metastasis.\nPresence of measurable disease by RECIST 1.1 criteria.\nNo prior systemic therapy for mCRC, except for neoadjuvant/adjuvant chemotherapy where > 6 months have elapsed between completion and recurrence.\nKnown pMMR/MSS status\nExclusion criteria:\nActive or prior documented autoimmune or inflammatory disorders or cardiac conditions.\nPrior history of hypertensive crisis or hypertensive encephalopathy or bleeding risks.\nDeep venous thrombosis, pulmonary embolism, arterial thrombosis, transient ischemic attack or cerebrovascular accident.\nPrior exposure to immune mediated therapy.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06792695",
      "Study status": "Active",
      "Schema image": "NCT06792695.png"
    },
    {
      "Disease Setting": "1st line ",
      "Trial Name": "WO42758 (INTRINSIC)",
      "Full title": "A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC).",
      "Additional notes": null,
      "Tissue Requirements": "Baseline tumor tissue samples will be collected from all participants.\nKRAD G12C mutation via local NGS.",
      "Trial Intervention/Arms": "A: Divarasib + Bevacizumab + FOLFOX \nB: Divarasib + Bevacizumab + FOLFIRI ",
      "Eligibility ": "Inclusion criteria:\n2 cycles of chemo allowed. \nMeasurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)\nKRAS G12C biomarker.\nExclusion criteria:\nAny systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment.\nUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\nClinically significant and active liver disease.\nHistory of malignancy other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT04929223",
      "Study status": "Active",
      "Schema image": "NCT04929223.png"
    },
    {
      "Disease Setting": "2nd line ",
      "Trial Name": "BOLD-100-001 (TRIO039)",
      "Full title": "A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours.",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Trial Intervention/Arms": "â€¢ Control Arm (FOLFOX alone)\nâ€¢ 500mg/m2 BOLD-100 + FOLFOX\nâ€¢ 625mg/m2 BOLD-100 + FOLFOX",
      "Eligibility ": "Inclusion criteria:\nMust have received only 1 prior line of therapy in the metastatic setting but remain naÃ¯ve to oxaliplatin prior to enrollment in this study.\nPrior oxaliplatin therapy is permitted in the following two situations: 1) Patients who have received oxaliplatin in the adjuvant setting. 2) Patients who have received oxaliplatin in the first line metastatic setting but did not progress on treatment or within 3 months of oxaliplatin treatment cessation.\nProgressing on 1st line FOLFIRI.\nHave measurable disease according to RECIST1.1 (at least one measurable lesion).\nExclusion criteria:\nPrevious intolerance to or significant reaction secondary to fluorouracil or oxaliplatin.\nPatients considered resistant to Oxaliplatin: â€¢ Patients who have received oxaliplatin in the adjuvant setting who have progressed / relapsed within 6 months of their last oxaliplatin administration.\nPatients with advanced colorectal cancer who have progressed (based on RECIST 1.1) while on or within 3 months of their last administration of oxaliplatin.\nAny other known malignancy within 3 years before the start of treatment (with the exception of non-melanoma skin cancer that had undergone curative treatment, cervical cancer in situ, or ductal/lobular carcinoma in situ of the breast that has underwent local treatment).\nActive gastrointestinal tract disease with malabsorption syndrome.\nTreatment with radiation therapy or surgery within 4 weeks prior to starting treatment.",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT04421820",
      "Study status": "Active",
      "Schema image": "NCT04421820.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "C4761001 ",
      "Full title": "A Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti tumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue of sufficient quality and quantity within 6 months of consent, otherwise fresh biopsy required during screening (sponsor can be asked to accept previous archival tissue if patient is not fit for additional biopsy).",
      "Trial Intervention/Arms": "C4761001 (Braf inhibitor) + cetuximab ",
      "Eligibility ": "Inclusion criteria:\nNo prior encorafenib exposure.\nBRAF V600E in tumor tissue and/or blood.\nDisease progressed during/following last prior treatment and no satisfactory alternative treatment options.\nExclusion criteria:\nSystemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\nConcurrent neuromuscular disorder associated with elevated creatine kinase (CK).",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT05355701",
      "Study status": "Active",
      "Schema image": "NCT05355701.png"
    },
    {
      "Disease Setting": "2nd line ",
      "Trial Name": "GSK223675 ",
      "Full title": "A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors.",
      "Additional notes": "CRC-A: Closed to enrollment\nCRC-B: On Pause",
      "Tissue Requirements": "Must provide tumor tissue from a newly obtained fresh biopsy or an archival tumor tissue.",
      "Trial Intervention/Arms": "GSK223675 (B7-H3 ADC) \nCRC-A Q3W (Closed)\nCRC-B Q2W (On Pause)",
      "Eligibility ": "Inclusion criteria:\nNo prior irinotecan exposure.\nLocally advanced or unresectable metastatic adenocarcinoma of the colon or rectum.\nMust have received at least 1 and no more than 2 lines of systemic treatment for advanced colorectal cancer (CRC), with documented progression on most recent prior line of therapy.\nExclusion criteria:\nHas a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas.\nHas had any major surgery within 28 days prior to randomization.\nHas severe, uncontrolled or active cardiovascular disorders.\nHas serious or poorly controlled hypertension.\nHas clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06885034",
      "Study status": "Not recruiting",
      "Schema image": "NCT06885034.png"
    },
    {
      "Disease Setting": "1st line ",
      "Trial Name": "ONO-4578-10",
      "Full title": "A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With OpdivoÂ® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer.",
      "Additional notes": null,
      "Tissue Requirements": "Central testing of biomarker",
      "Trial Intervention/Arms": "A: ONO-4578  20 mg + Nivolumab + Bevacizumab + FOLFOX\nB: ONO-4578 40 mg + Nivolumab + Bevacizumab + FOLFOX\nC: FOLFOX + Bevacizumab",
      "Eligibility ": "Inclusion criteria:\nHistologically confirmed locally advanced or mCRC.\nNo prior systemic treatment for advanced local or mCRC.\nParticipants whose tumor is positive for PD-L1 expression as determined at a central laboratory, CPS > 1 (expected to be 40%).\nExclusion criteria:\nMSI-High or dMMR tumor.\nParticipants with BRAF V600E mutation.\nPrior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06948448",
      "Study status": "Active",
      "Schema image": "NCT06948448.png"
    },
    {
      "Disease Setting": "Last line",
      "Trial Name": "CO.33 (BATTMAN)",
      "Full title": "Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial",
      "Additional notes": null,
      "Tissue Requirements": "Archival formalin fixed paraffin block of tumour tissue for correlative analyses when tumour tissue is available.",
      "Trial Intervention/Arms": "A: BOTENSILIMAB + BALSTILIMAB \nB: Best supportive care",
      "Eligibility ": "Inclusion criteria:\nCRC that is not dMMRor MSI-H.\nReceived and failed all prior available therapies, such that the standard of care for the patient would be best supportive care (BSC).\nPresence of measurable or evaluable disease as RECIST 1.1.\nExclusion criteria:\nHistory of primary immunodeficiency, solid organ transplant or allogeneic bone marrow transplant.\nCurrent or prior use of immunosuppressive medication within 7 days before the first dose.\nActive brain metastases or leptomeningeal metastases.\nReceipt of anti-cancer chemotherapy or biologic therapy within the lesser of i) 21 days, or ii) the usual cycle length of the regimen prior to the first planned dose of study drug.\nPrior exposure to anti-PD-1/PD-L1/CTLA-4 therapy.",
      "Contacts": "Site PI:\nSanz Enrique\nenrique.sanz@uhn.ca",
      "NCT number": "NCT07152821",
      "Study status": "Active",
      "Schema image": "NCT07152821.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "Debio 0123-106",
      "Full title": "Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)",
      "Additional notes": "This is a Phase 1/1b, multi-center, open-label study to evaluate the safety, tolerability, PK,\npharmacodynamics, and preliminary efficacy of lunresertib in combination with Debio 0123, a WEE1 kinase inhibitor. The module will be conducted in 2 parts (4a and 4b): dose escalation (Module 4a) in patients with advanced solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A.\n\nThe study is no longer testing combination of lunresertib and RP-3500 on participants. ",
      "Tissue Requirements": "Archived tumor tissue sample available or lesion that can be safely biopsied if the archival sample is not available. There are no specific requirements for tissue type, but sample needs to have 30% tumour content. Archival sample are to be prepared into 20 slides for IHC, FISH, and DNA/RNA extraction. \n\nPatients who do not have archival sample and biopsy collection are not feasible due to safety reason are still possible to be screen for the study after consultation with study Sponsor. ",
      "Trial Intervention/Arms": "Patient will be assign to only one dosing schedule - lunresertib in combination with Debio 0123 on the 3 days on/4 days off dosing for two weeks, followed by a week break (2 week on/1 week off). Dosage of lunresertib and Debio0123 may vary.",
      "Eligibility ": "Inclusion Criteria:\n- Male or female and â‰¥12 years-of-age at the time of signature of the ICF.\n- ECOG Performance Status score of 0 or 1. Lansky performance status â‰¥50 for patients â‰¤16 years of age\n- Patients are eligible if, in the opinion of the Investigator, the patient is not a candidate for,\nor would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or if the patient declines standard-of-care therapy. Documented counselling by the center Investigator on benefits/risks of standard-of-care therapy is required for enrolled patients who decline standard-of-care therapy.\n- Measurable disease as per RECIST v1.1.\n- Ability to swallow and retain oral tablets and capsules whole and intact.\n- Hemoglobin â‰¥10.0 g/dL except if anemia is due to potentially reversible and manageable etiology (e.g. bleeding from tumor lesion)\n- Creatinine clearance â‰¥60 mL/min calculated using Cockcroft-Gault equation or measured by 24-hour urine collection. For patients 12 to 17 years of age, renal function should be calculated using Cockcroft-Gault or institutional standard, including institutional formula specific for this age group.\n\nExclusion Criteria:\n- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 halflives,\nand monoclonal antibodies given within 28 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.\n- Presence of other known second malignancy with the exception of any cancer that has been in complete remission for â‰¥ 2 years or completely resected squamous and basal cell carcinomas of the skin.\n- Prior therapy with a PKMYT1 or WEE1 inhibitor.\n- Patients who are unable to swallow oral tablets and capsules whole and intact\n- Clinically significant gastrointestinal abnormality that would affect the absorption of drugs, such as malabsorption syndrome, major resection of the small bowel, total gastrectomy, or inflammatory bowel disease.\n- Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of study drug.\n- Uncontrolled, symptomatic brain metastases.\n- Uncontrolled hypertension (systolic blood pressure â‰¥160 mmHg; diastolic blood pressure â‰¥100 mmHg) despite adequate treatment prior to first dose of study drug.\n- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.\n- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).\n- Mean resting QT interval corrected for heart rate (QTc) interval using the Fridericia formula (QTcF) >450 msec (as calculated per institutional standards) obtained from 3 ECGs â‰¥1 minute apart at study entry.\n- Current treatment with medications that are well-known to prolong the QT interval or with known risk of TdP (Appendix 2). If patients are on these medications, a wash-out period of at least 5 half-lives is needed prior to receiving the treatment.\n- Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccine.",
      "Contacts": "PI: Dr. Stephanie Lheureux\n416-946-2818\nStephanie.Lheureux@uhn.ca\nStudy Coordinator: Vivian Feng\nvivian.feng2@uhn.ca",
      "NCT number": "NCT04855656",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2L+",
      "Trial Name": "Phase 1 of NDI-219216 in Patients with Advanced Solid Tumors with MSI-H/dMMR",
      "Full title": "A Phase 1 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair",
      "Additional notes": "Solid tumor patients with MSI-H/dMMR\nProgressed or intolerant of SOC",
      "Tissue Requirements": "Archival tissue",
      "Trial Intervention/Arms": "NDI-219216 (Werner helicase inhibitor) orally daily ",
      "Eligibility ": "MSI-H/dMMR\nProgressed or intolerant of SOC",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06898450",
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "GE": [
    {
      "Disease Setting": "Prior to any systemic treatment ",
      "Trial Name": "MOCHA",
      "Full title": "Molecular characteristics of gastroesophageal adenocarcinoma ",
      "Additional notes": "Prospective collection of clinical data, bloods, stool, and tissue ",
      "Tissue Requirements": "Baseline fresh tissue biopsy ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm 1: localized and resectable gastroesophageal adenocarcinoma \nArm 2: metastatic/unresectable gastroesophageal adenocarcinoma",
      "Eligibility ": "Chemotherapy-naive patients \nArm 1: \nLocalized GE amenable to curative intent therapy with surgery as standard of care, either with or without induction chemotherapy or chemo radiotherapy\nArm 2: \nMinimum of 3 x 18G good quality tumour cores at biopsy\nMust have a measurable lesion by RECIST 1.1\nPatients plan to undergo systemic treatment with platinum-based chemotherapy ",
      "Contacts": "Site PI:\nJonathan Yeung (Arm 1)\n\nElena Elimova\nelena.elimova@uhn.ca (Arm 2)",
      "NCT number": "NCT04219137",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "3L+",
      "Trial Name": "Clarity-Gastric01 ",
      "Full title": "A Phase III Multi-center, Open-label, Sponsor-blinded, \nRandomized Study of AZD0901 Monotherapy Compared with \nInvestigatorâ€™s Choice of Therapy in Second- or Later-Line Adult \nParticipants with Advanced/Metastatic Gastric or \nGastroesophageal Junction Adenocarcinoma Expressing \nClaudin18.2",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue (â‰¤24 months); fresh tissue (3xT cores) ",
      "Biomarker/unselected": "CLDN18.2",
      "Trial Intervention/Arms": "AZD0901 vs physicianâ€™s choice \nArm 1: Participants in the AZD0901 arm 1 will receive 2.2 mg/kg AZD0901 IV, Q3W\nArm 2: Participants in the AZD0901 arm 2 will receive 1.8 mg/kg AZD0901 IV, Q3W (Discontinued following dose selection made on Jan 2025)\n Arm 3: Regimen of \nInvestigatorâ€™s choice. These include:\n- 2L: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W\n- 2L: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)\n- 2L: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)\n- 3L+: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W [As of 16Jul25, Slot Request Form need to be sent to sponsor for eligibility]",
      "Eligibility ": "Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.\nMust have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1.",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT06346392",
      "Study status": "Active",
      "Schema image": "NCT06346392.png"
    },
    {
      "Disease Setting": "1st line",
      "Trial Name": "ARTEMIDE-Gastric01 ",
      "Full title": "A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer ",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue (â‰¤6 months); fresh tissue (3xT cores) ",
      "Biomarker/unselected": "HER2 and PDL1",
      "Trial Intervention/Arms": "A: Rilve + T-DXd + 5FU/Cape\nB: Pembro + tras + 5FU/Cape + platinum \nC: Rilve + tras + 5FU/Cape + platinum",
      "Eligibility ": "Her-2 + and PDL1 CPS â‰¥ 1. \nPreviously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma.\nHave measurable target disease assessed by the Investigator based on RECIST v1.1.\nLVEF â‰¥ 55% within 28 days before randomization.",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT06764875",
      "Study status": "Active",
      "Schema image": "NCT06764875.png"
    },
    {
      "Disease Setting": "2L+",
      "Trial Name": "GA.4 ",
      "Full title": "A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue (most recent or as per MRP/PIâ€™s discretion); fresh tissue (2xT cores for screening; 3xT cores optional biopsy) ",
      "Biomarker/unselected": "HER2 ",
      "Trial Intervention/Arms": "ARM 1 - Standard Chemotherapy (Paclitaxel + Ramucirumab)                                                     \nARM 2 - Standard Chemotherapy (Paclitaxel + Ramucirumab) plus Zanidatamab",
      "Eligibility ": "Her-2 + (central confirmation).\nParticipants must have received and failed at least one prior trastuzumab-containing regimen in combination with platinum-based chemotherapy.\nmust have presence of measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1).",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT06043427",
      "Study status": "Active",
      "Schema image": "NCT06043427.png"
    },
    {
      "Disease Setting": "Any line ",
      "Trial Name": "TORO ",
      "Full title": "Chemoimmunotherapy followed by Surgery for Oligometastatic Esophageal and Gastric Cancer: A Phase II Clinical Trial",
      "Additional notes": null,
      "Tissue Requirements": "None",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Systemic treatment for minimum of 6 months or to maximal response, followed by esophagectomy and resection/SBRT of any mets.",
      "Eligibility ": "Oligometastatic disease (up to 5 sites).\nHistologically-proven cT1-4aN0-3M1 adenocarcinoma or squamous cell carcinoma of the esophagus, or EGJ",
      "Contacts": "Site PI:\nElliot Wakeam\nelliot.wakeam@uhn.ca",
      "NCT number": "NCT06668454",
      "Study status": "Active",
      "Schema image": "NCT06668454.png"
    },
    {
      "Disease Setting": "3L+",
      "Trial Name": "REJOICE-GI01",
      "Full title": "A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue (â‰¤5 years); fresh tissue (3xT cores) ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Raludotatug Deruxtecan (R-DXd, CDH6 targeting ADC)",
      "Eligibility ": "Has one of the following: gastric, gastroesophageal junction or esophageal adenocarcinoma.\nHas received prior therapy for the cancer\nNot biomarker selected.\nExcluded if have a known additional malignancy that is progressing or has required active treatment within the past 3 years.\nPatients with previous topoisomerase 1 inhibitor are excluded.",
      "Contacts": "Site PI:\nLucy Ma\nlucy.ma@uhn.ca",
      "NCT number": "NCT06864169",
      "Study status": "Active",
      "Schema image": "NCT06864169.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "GEAR",
      "Full title": "Gastroesophageal and Endocrine Cancer Registry ",
      "Additional notes": "Prospective collection of clinical data, bloods, stool, and tissue ",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": null,
      "Eligibility ": "Those who decline or are or not eligible for MOCHA ",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "N/A",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Prior to any treatment ",
      "Trial Name": "IRONGOOSE",
      "Full title": "The Incidence of Iron Deficiency Anemia Across the Continuum of Care in Adult Patients Undergoing Treatment for Esophageal Cancer",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": null,
      "Eligibility ": "Diagnosed with esophageal cancer and gastroesophageal junction cancer who are scheduled to undergo treatment including surgery, radiation therapy, chemotherapy, or any combination of these modalities",
      "Contacts": "Site PI:\nElliot Wakeam\nelliot.wakeam@uhn.ca",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Curative",
      "Trial Name": "DEFEAT",
      "Full title": "Deciphering Factors of Treatment Resistance in Gastrointestinal Cancers",
      "Additional notes": "Prospective collection of clinical data, tissue",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": null,
      "Eligibility ": "Undergoing a curative-intent resection or biopsy of gastric, colorectal, or small bowel cancer",
      "Contacts": "Site PI:\nKarineh Kazazian\nkarineh.kazazian@uhn.ca",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Curative",
      "Trial Name": "NEEDS",
      "Full title": "Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Neoadjuvant chemoradiotherapy + surgery vs definitive chemoradiotherapy + salvage surgery (if needed)",
      "Eligibility ": "Histopathologically confirmed SCC of the esophagus in locally advanced stages cT1 N+ or cT2-4a any N, M0, according to current (8th) version of of the AJCC TNM classification.",
      "Contacts": "Site PI:\nJelena Lukovic\njelena.lukovic@uhn.ca",
      "NCT number": "NCT04460352",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1L",
      "Trial Name": "DESTINY-Gastric03",
      "Full title": "A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": "HER2",
      "Trial Intervention/Arms": "Part 5: T-DXd + volrustomig ",
      "Eligibility ": "Her-2 overexpression.\nILD/Pneumonitis excluded.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca",
      "NCT number": "NCT04379596",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1L ",
      "Trial Name": "AndroMETa-GEA-977",
      "Full title": "A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of \nTelisotuzumab Adizutecan in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line \nTreatment in Subjects with Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal \nJunction, or Esophageal Adenocarcinoma",
      "Additional notes": null,
      "Tissue Requirements": "Archival tissue (most recent); fresh tissue 3xT cores",
      "Biomarker/unselected": "c-Met",
      "Trial Intervention/Arms": "FOLFOX + budi vs Telisotuzumab adizutecan + budi + 5-FU + LV",
      "Eligibility ": "Have inoperable, advanced or metastatic histologically- or cytologically confirmed gastric, gastroesophageal junction, or esophageal adenocarcinoma. HER2 negative",
      "Contacts": "Site PI: \nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT06628310",
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "HCC": [
    {
      "Disease Setting": "Peri-OR",
      "Trial Name": "NEOTOMA",
      "Full title": "Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with\nResectable Hepatocellular Carcinoma (HCC) - A Phase II Trial",
      "Additional notes": null,
      "Tissue Requirements": "Baseline biopsy: Fresh tissue will be collected at screening. If possible, at least 4 cores but preferably 6. ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Pre-surgery: x1 dose Tremelimumab (300mg) + Durvalumab (1500mg), x1 dose Durva only. \n\nPost-surgery: 11 cycles of Durvalumab Q4W. ",
      "Eligibility ": "Resectable HCC. \nNo prior therapy, except for a single liver resection or ablation performed at least two years before study enrollment.\nMust consent to provide biopsy sample prior to treatment.\nChild Pugh 5 or 6, ALBI grade 1",
      "Contacts": "Site PI:\nAnand Ghanekar\nanand.ghanekar@uhn.ca\n\nCoordinators: \nMary Wei\nGuillaume Cheung\n\nShiva Babakhani\nGiselle Caballero",
      "NCT number": "NCT05440864",
      "Study status": "Active",
      "Schema image": "NCT05440864.png"
    },
    {
      "Disease Setting": "Pre-transplant",
      "Trial Name": "BeyondIO (HMLTO002)",
      "Full title": "Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study",
      "Additional notes": null,
      "Tissue Requirements": "Baseline biopsy: fresh, or archival if tissue available for correlatives.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Atezolizumab (1200mg) + Bevacizumab (15mg/kg) Q3W plus TACE or TARE during liver transplant waiting period",
      "Eligibility ": "HCC, candidate for liver transplant by Toronto criteria, but beyond Milan criteria.\nChild-Pugh score â‰¤A6.\nToronto Critera: TTV<145 cm3, AFP<1000",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca\n\nCoordinator:\nGuillaume Cheung",
      "NCT number": "NCT05185505",
      "Study status": "Active",
      "Schema image": "NCT05185505.png"
    },
    {
      "Disease Setting": "1st line",
      "Trial Name": "ARTEMIDE HCC01",
      "Full title": "A Phase III Randomised, Open Label, Sponsor-Blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma",
      "Additional notes": "ON HOLD. \nSafety Run In has closed. Decision to proceed to next phase will be mid-December. ",
      "Tissue Requirements": "FFPE tumor tissue sample - newly acquired or archival <12 months prior to screening. \n\nIf no FFPE block available, newly-cut tissue sections on unstained slides. 3-4 tumor cores. ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "â€¢ Arm A: Tremelimumab 300 mg Ã— 2 doses (Q12W), rilvegostomig 750 mg Q3W, and bevacizumab 15 mg/kg Q3W (bevacizumab will not be given in cycles with tremelimumab) \nâ€¢ Arm B: Rilvegostomig 750 mg Q3W, and bevacizumab 15 mg/kg Q3W \nâ€¢ Arm C: Atezolizumab 1200 mg Q3W, and bevacizumab 15 mg/kg Q3W",
      "Eligibility ": "HCC, no prior systemic therapy. \nNo main portal vein thrombosis (no VP4).\nCP-A.",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nCoordinator:\nOchir Gansukh",
      "NCT number": "NCT06921785",
      "Study status": "Not Recruiting",
      "Schema image": "NCT06921785.png"
    },
    {
      "Disease Setting": "1st Line ",
      "Trial Name": "HE.2",
      "Full title": "A Phase II Study of STRIDE (Durvalumab + Tremelimumab) with Lenvatinib Versus Stride Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)",
      "Additional notes": null,
      "Tissue Requirements": "Archival tumor tissue (optional). \n\n1 FFPE block, >30% cellularity, sufficient for 20 x 5-10 micron sections to be cut. \n\nTo be submitted within 4 weeks after randomization. ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "ARM 1: STRIDE (durvalumab + tremelimumab at first treatment followed by durvalumab monotherapy every 4 weeks)\n\nARM 2: STRIDE + lenvatinib daily\n",
      "Eligibility ": "HCC, no prior systemic therapy. \nChild-Pugh Score class A or B7 based on low albumin (albumin 25-27 g/L) only.\nConfirmed HCC based on histopathological findings from tumour tissues or clinically by AASLD criteria in cirrhotic participants (must be CT LIRADS 5 on CT; otherwise needs histology).",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nCoordinator:\nDowon Choi",
      "NCT number": "NCT06880523",
      "Study status": "Active",
      "Schema image": "NCT06880523.png"
    },
    {
      "Disease Setting": "1st line ",
      "Trial Name": "CHS-388-202",
      "Full title": "A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma ",
      "Additional notes": null,
      "Tissue Requirements": "Baseline biopsy mandatory. \nArchival FFPE block (less than two years old), if unavailable, fresh biopsy, 3-5 cores. \n\nOn-treatment biopsy (collect between C2D1 post-dosing - C2D15): if medically feasible \n\nEOT or disease progression biopsy: Optional \n",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "â€¢ Arm A: casdozokitug 700 mg + toripalimab 240 mg + bevacizumab 15 mg/kg intravenously (IV) every 3 weeks (Q3W) on Day 1 of a 21-day cycle (n ~ 24). \nâ€¢ Arm B: casdozokitug 1400 mg + toripalimab 240 mg + bevacizumab 15 mg/kg IV Q3W on Day 1 of a 21-day cycle (n ~ 24). \nâ€¢ Arm C: toripalimab 240 mg + bevacizumab 15 mg/kg IV Q3W on Day 1 of a 21-day cycle (n ~ 24) ",
      "Eligibility ": "Unresectable, locally advanced or metastatic HCC. No prior systemic therapy. ",
      "Contacts": "Site PI: \nDr. Erica Tsang\nerica.tsang@uhn.ca\n416-946-4501 ext. 4853\n\nCoordinator: \nMary Wei",
      "NCT number": "NCT06679985",
      "Study status": "Active",
      "Schema image": "NCT06679985.png"
    },
    {
      "Disease Setting": "1st or 2nd",
      "Trial Name": "CaboTx\n ",
      "Full title": "A Phase II Trial of Cabozantinib in the Treatment of Recurrent Hepatocellular Carcinoma Post Liver Transplant",
      "Additional notes": null,
      "Tissue Requirements": "Baseline biopsy: 4 cores will be collected during screening period.  \nPlus, original explant archival tissue (FFPE block is preferred).",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Cabozanitnib",
      "Eligibility ": "Recurrence after transplant. May be systemic therapy naÃ¯ve or have received up to 1 line of prior therapy for advanced HCC with sorafenib or lenvatinib.",
      "Contacts": "Site PIs:\nRobert Grant\nrobert.grant@uhn.ca\n\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nCoordinator: \nSerena Kao ",
      "NCT number": "NCT04204850",
      "Study status": "Active",
      "Schema image": "NCT04204850.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "TYR430-101",
      "Full title": "A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations",
      "Additional notes": "Participating in Part A\n\nWaitlist for spots. ",
      "Tissue Requirements": "Archival FFPE block (less than two years old). If unavailable, fresh biopsy if deemed medically safe by physician. ",
      "Biomarker/unselected": "FGF/FGFR",
      "Trial Intervention/Arms": "TYRA-430",
      "Eligibility ": "Adults with histologically confirmed HCC, or advanced solid tumors with any FGF/FGFR pathway alteration.\nChild-Pugh Score class A.",
      "Contacts": "Site PI:\nArdnt Vogel\nardnt.vogel@uhn.ca\n\nCoordinator: \nStephen Lam",
      "NCT number": "NCT06915753",
      "Study status": "Active",
      "Schema image": "NCT06915753.png"
    },
    {
      "Disease Setting": "Last line",
      "Trial Name": "ITER-002-HCC",
      "Full title": "A phase 1/2 exploratory study of the TBL1 inhibitor, tegavivint (BC2059), in patients with advanced hepatocellular carcinoma",
      "Additional notes": null,
      "Tissue Requirements": "Pre-treatment biopsy (within 21 days of cycle 1 day 1) and post treatment biopsy (Cycle 2 Day 15 Â± 7) is required for all patients. FFPE block or 20 x 5-micron slides.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Tegavivint (BC2059), or tegavivint+pembrolizumab ",
      "Eligibility ": "Advanced HCC after failure/intolerance/contraindication to at least one prior line of systemic therapy. \nCTNNB1, APC or AXIN1 mutations, except on single agent dose escalation. \nChild-Pugh class A or â‰¤ 7 class B liver score (no hepatic encephalopathy) within 7 days of first dose of the investigational product(s).",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501\n\nCoordinator: \nGuillaume Cheung",
      "NCT number": "NCT05797805",
      "Study status": "Active",
      "Schema image": "NCT05797805.png"
    },
    {
      "Disease Setting": "2nd",
      "Trial Name": "BANTAM-01",
      "Full title": "A multicenter, open label, non-randomized first-in-human phase 1 dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of BAY 3547926 alone, and in combination, in participants with advanced hepatocellular carcinoma (HCC)",
      "Additional notes": "This is a Phase 1, open-label, non-randomized, first-in-human study in participants with advanced hepatocellular carcinoma (HCC). \n\nThe purpose of the study is to evaluate the safety, tolerability, PK, anti-tumour activity of BAY 3547926 alone, and in combination in this patient population. \n\nThe study will have 3 phases.\n1. Part 1: Dose Escalation\n2. Part 2: Dose Expansion as monotherapy \n3. Part 3: Dose Expansion in combination with Atezolizumab and Bevacizumab \n\nThe study aims to enroll up to 148 participants globally. Each participants will follow the pre-screening period to test whether they have the particular protein, called GCP3 protein, in their tumor cells, a screening period, study intervention period, active follow-up period and long-term follow-up period. The study duration for each participant will be 48 months in part 1 and 2. Participants will continue to receive the study intervention until disease progression, or they experience unacceptable side effects or if they withdraw from the study.",
      "Tissue Requirements": "Tumor tissue biopsy at pre-screening/screening, C2D8 and EOT - at least 4 cores of at least 20 mm in length (less cores are acceptable if collection of more material is not possible). \nCentral testing of tumor tissue GPC3 expression",
      "Biomarker/unselected": "GPC3",
      "Trial Intervention/Arms": "Part 1 - Dose Escalation: No statistical hypotheses will be tested for this part of the study. \nPart 2 and 3 - Dose Expansion: A Bayesian statistical hypothesis of the form  H0:Ï€â‰¤Ï€0 and H1:Ï€>Ï€0, is followed to assess the significance of efficacy related evidence in each cohort. \nPart 2 - Assuming a minimum threshold of ORR (Ï€0) of 15% that is the assumed standard of care ORR in the target population considered to be promising, the following hypotheses will be tested: H0:ð‘‚ð‘…ð‘…â‰¤15% ð‘£ð‘  H1:ð‘‚ð‘…ð‘…>15%. And in part 3, Assuming a minimum threshold of ORR (Ï€0) of 30% that is the assumed standard of care ORR in this population considered to be promising, the following hypotheses will be tested: H0:ð‘‚ð‘…ð‘…â‰¤30% ð‘£ð‘  H1:ð‘‚ð‘…ð‘…>30%.",
      "Eligibility ": "Inclusion Criteria:\nLA or met and/or unresectable HCC, or non-invasive diagnosis as per AASLD criteria in participants with a confirmed diagnosis of cirrhosis.\nPositive centrally confirmed GPC3 expression by IHC on tumor sample.\nAny local or loco-regional therapy of intrahepatic tumor lesions must have been completed â‰¥ 4 weeks prior to treatment initiation.\nECOG 0-1.\nAt least one measurable lesion by CT scan or MRI according to RECIST 1.1. as assessed by local site Investigator within 28 days prior to the start of the study treatment. \nExclusion Criteria:\nFibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular/cholangiocarcinoma subtypes.\nParticipants with a history or clinical evidence of CNS metastases, unless they meet specific criteria.\nHistory of encephalopathy â‰¥ Grade 2 within the past 12 months.\nClinically significant ascites.",
      "Contacts": "Site PI:\nDr. Arndt Vogel\nArndt.Vogel@uhn.ca\nCoordinator:\nRegulatory & Data: Sylvia Tran\nSylvia.Tran@uhn.ca\nStudy Nurse: Ochir Gansukh\nOchir.Gansukh@uhn.ca",
      "NCT number": "NCT06764316",
      "Study status": "Active",
      "Schema image": "NCT06764316.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "Debio 0123-106",
      "Full title": "Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)",
      "Additional notes": "This is a Phase 1/1b, multi-center, open-label study to evaluate the safety, tolerability, PK,\npharmacodynamics, and preliminary efficacy of lunresertib in combination with Debio 0123, a WEE1 kinase inhibitor. The module will be conducted in 2 parts (4a and 4b): dose escalation (Module 4a) in patients with advanced solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A.\n\nThe study is no longer testing combination of lunresertib and RP-3500 on participants. ",
      "Tissue Requirements": "Archived tumor tissue sample available or lesion that can be safely biopsied if the archival sample is not available. There are no specific requirements for tissue type, but sample needs to have 30% tumour content. Archival sample are to be prepared into 20 slides for IHC, FISH, and DNA/RNA extraction. \n\nPatients who do not have archival sample and biopsy collection are not feasible due to safety reason are still possible to be screen for the study after consultation with study Sponsor. ",
      "Biomarker/unselected": "One of: CCNE1 amplification; FBXW7 deleterious mutations, or PPP2R1A deleterious mutations.",
      "Trial Intervention/Arms": "Patient will be assign to only one dosing schedule - lunresertib in combination with Debio 0123 on the 3 days on/4 days off dosing for two weeks, followed by a week break (2 week on/1 week off). Dosage of lunresertib and Debio0123 may vary.",
      "Eligibility ": "Inclusion Criteria:\n- Male or female and â‰¥12 years-of-age at the time of signature of the ICF.\n- ECOG Performance Status score of 0 or 1. Lansky performance status â‰¥50 for patients â‰¤16 years of age\n- Patients are eligible if, in the opinion of the Investigator, the patient is not a candidate for,\nor would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or if the patient declines standard-of-care therapy. Documented counselling by the center Investigator on benefits/risks of standard-of-care therapy is required for enrolled patients who decline standard-of-care therapy.\n- Measurable disease as per RECIST v1.1.\n- Ability to swallow and retain oral tablets and capsules whole and intact.\n- Hemoglobin â‰¥10.0 g/dL except if anemia is due to potentially reversible and manageable etiology (e.g. bleeding from tumor lesion)\n- Creatinine clearance â‰¥60 mL/min calculated using Cockcroft-Gault equation or measured by 24-hour urine collection. For patients 12 to 17 years of age, renal function should be calculated using Cockcroft-Gault or institutional standard, including institutional formula specific for this age group.\n\nExclusion Criteria:\n- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 halflives,\nand monoclonal antibodies given within 28 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.\n- Presence of other known second malignancy with the exception of any cancer that has been in complete remission for â‰¥ 2 years or completely resected squamous and basal cell carcinomas of the skin.\n- Prior therapy with a PKMYT1 or WEE1 inhibitor.\n- Patients who are unable to swallow oral tablets and capsules whole and intact\n- Clinically significant gastrointestinal abnormality that would affect the absorption of drugs, such as malabsorption syndrome, major resection of the small bowel, total gastrectomy, or inflammatory bowel disease.\n- Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of study drug.\n- Uncontrolled, symptomatic brain metastases.\n- Uncontrolled hypertension (systolic blood pressure â‰¥160 mmHg; diastolic blood pressure â‰¥100 mmHg) despite adequate treatment prior to first dose of study drug.\n- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.\n- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).\n- Mean resting QT interval corrected for heart rate (QTc) interval using the Fridericia formula (QTcF) >450 msec (as calculated per institutional standards) obtained from 3 ECGs â‰¥1 minute apart at study entry.\n- Current treatment with medications that are well-known to prolong the QT interval or with known risk of TdP (Appendix 2). If patients are on these medications, a wash-out period of at least 5 half-lives is needed prior to receiving the treatment.\n- Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccine.",
      "Contacts": "PI: Dr. Stephanie Lheureux\n416-946-2818\nStephanie.Lheureux@uhn.ca\nStudy Coordinator: Vivian Feng\nvivian.feng2@uhn.ca",
      "NCT number": "NCT04855656",
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "CCA": [
    {
      "Disease Setting": "Adjuvant",
      "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
      "Full title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)",
      "Additional notes": "UHN has reached target enrollment. Additional slots may be available - request from Sponsor",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "A: rilvegostomig + SOC\nB: placebo + SOC",
      "Eligibility ": "R0/R1 resection, within 12 weeks\nNo ampullary/NET",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131",
      "NCT number": "NCT06109779",
      "Study status": "Not Recruiting",
      "Schema image": "NCT06109779.png"
    },
    {
      "Disease Setting": "1st line",
      "Trial Name": "Destiny-BTC01",
      "Full title": "DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": "Her-2+",
      "Trial Intervention/Arms": "A: TdXD + rilvegostomig\nB: TdXD\nC: GemCis/Durva",
      "Eligibility ": "Unresectable, previously untreated,locally advanced or metastatic\nHer-2+",
      "Contacts": "Site PI:\nErica Tsang\nerica.tsang@uhn.ca",
      "NCT number": "NCT06467357",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1st line",
      "Trial Name": "\nHERIZON-BTC-302 (Sponsor: Jazz pharma)",
      "Full title": "An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer",
      "Additional notes": "Patient must be randomized before starting C3. ",
      "Tissue Requirements": "Fresh biopsy or archival (up to 6 months old). ",
      "Biomarker/unselected": "Her-2+",
      "Trial Intervention/Arms": "A: ZW25 + SOC\nB: SOC",
      "Eligibility ": "Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation,or ablative therapies.\nReceived no more than 2 cycles of systemic therapy which is limited to Cisplatin and Gemcitabine (CisGem) with or without a PD-1/L1 inhibitor\nAssessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).\n",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca \nTrial Nurse: Guillaume\nguillaume.cheung@uhn.ca",
      "NCT number": "NCT06282575",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2nd or 3rd line",
      "Trial Name": "CLARITY-PanTumour01",
      "Full title": "A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)",
      "Additional notes": "BTC cohort:\nPre-screening & screening on hold until end of Q1 2026.",
      "Tissue Requirements": null,
      "Biomarker/unselected": "CLDN18.2",
      "Trial Intervention/Arms": "AZD0901 monotherapy",
      "Eligibility ": "Claudin 18.2+\nPrior exposure to any CLDN18.2 targeted agents except anti-\nCLDN18.2 monoclonal antibody are excluded\nMust have at least one measurable lesion according to RECIST v1.1.",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca",
      "NCT number": "NCT06219941",
      "Study status": "Not Recruiting",
      "Schema image": null
    },
    {
      "Disease Setting": "2nd line",
      "Trial Name": "ProvIHDe",
      "Full title": "An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma",
      "Additional notes": "PMH slots have been filled. Request additional slot from Sponsor",
      "Tissue Requirements": null,
      "Biomarker/unselected": "IDH1",
      "Trial Intervention/Arms": "Ivosidenib",
      "Eligibility ": "IDH1+\nNot eligible for curative-intent resection, transplantation, or ablative therapies\nHave tried at least 1 prior type of systemic therapy for CCA, and have recovered from any side effects\nExcluded if received a prior IDH1 inhibitor or a transplant",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca",
      "NCT number": "NCT05876754",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "CGT4859 ",
      "Full title": "A Phase I/II Study of an FGFR2/â€‹3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": "FGFR2\nFGFR3",
      "Trial Intervention/Arms": "CGT4859 ",
      "Eligibility ": "FGFR2 fusions.\nExcluded if received more than 2 prior FGFRi therapies.\nHave measurable disease per RECIST v1.1.\n",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca\nPrimary CRC:\nStephen Lam\nstephen.lam@uhn.ca",
      "NCT number": "NCT06777316",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "SURF-431",
      "Full title": "A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": "FGF/FGFR",
      "Trial Intervention/Arms": "TYR430",
      "Eligibility ": "FGF/FGFR pathway alteration",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca",
      "NCT number": "NCT06915753",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2nd or later lines",
      "Trial Name": "FOENIX-CCA4 \nTAS-120-205",
      "Full title": "Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with \nAdvanced Cholangiocarcinoma with FGFR2 Fusions or \nRearrangements\n",
      "Additional notes": null,
      "Tissue Requirements": "Blood sample for ctDNA. Testing by FoundationOne CDx.  ",
      "Biomarker/unselected": "FGFR2 gene fusions;\nFGFR2  or other rearrangements using NGS or FISH",
      "Trial Intervention/Arms": "A:  20 mg futibatinib orally\nB: 16 mg  futibatinib orally \n",
      "Eligibility ": "Prior Gem/Cis treatment; Histological or cytological diagnosis of iCCA or eCCA; If FGFR status unknown, can submit archival tissue or blood for testing by Sponsor, if patient meets criteria. ",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca",
      "NCT number": "NCT05727176",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1st line",
      "Trial Name": "S095031-210",
      "Full title": "Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarcinoma with an IDH1 Mutation",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Biomarker/unselected": "IDH1",
      "Trial Intervention/Arms": "Ivosidenib + GemCis/Durva",
      "Eligibility ": "histologically-confirmed cholangio; \nlocally or centrally confirmed IDH1 mutation\nTreatment with up to one cycle of durvalumab plus gemcitabine/cisplatin treatment is permitted before study participation. ",
      "Contacts": "Site PI:\nArndt Vogel\narndt.vogel@uhn.ca\nTrial Nurse:\nSerena (Ching) Kao\nChing.Kao@uhn.ca\n",
      "NCT number": "NCT06501625",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "CAN-PREFER",
      "Full title": "Cancer Analysis Neural Networks for Patient Referenced Explanations of Findings from Expert Reports: A Randomized Control Trial of Patient-Facing, Large Language Model-Generated Summaries of Cancer Genomic Testing.",
      "Additional notes": "A single-center, dual-arm, prospective, randomized study.\nPatients with a current diagnosis of any stage of pancreatic or biliary tract cancer who are undergoing genomic biomarker testing as part of their cancer care.",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm 1: SoC clinical genomic testing reports alone.\nArm 2: SoC genomic testing reports + LLM-generated patient-facing\nreport summaries.\nStudy questionnaire sent when enrolled (resent for the re-test subset)",
      "Eligibility ": "Age >18 years.\nDiagnosis of biliary tract or pancreatic cancer at any stage, confirmed by pathology, radiology or multidisciplinary review.\nUnderwent genomic testing at UHN through the Prosper-PANC Study, HPB Tissue Banking Study or LeGresley Biliary Registry.\nAble to read and understand English.",
      "Contacts": "Site PI:\nRobert Grant\nrobert.grant@uhn.ca\n\nCoordinator:\nErin Winter\nErin.Winter@uhn.ca",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "PDAC": [
    {
      "Disease Setting": "Resectable",
      "Trial Name": "DORA (WOO)",
      "Full title": "Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA)",
      "Additional notes": "Resectable pancreatic cancer by NCCN criteria.\nCA 19-9 < 300.",
      "Tissue Requirements": "Baseline EUS biopsy\n4 cores required",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Durvalumab 1500 mg IV x 1 dose and oleclumab 3000 mg x 2 doses Q2W prior to resection",
      "Eligibility ": "Inclusion: \nResectable PDAC by NCCN criteria \nCA 19-9 < 300\nLife expectancy â‰¥ 12 weeks\n\nExclusion: \nAnticancer therapy within 21 days or palliative RT within 14 days prior to 1st dose\n\nPrior receipt of any immune-mediated therapy\n\nOther invasive malignancy within 5 years\n\nPrior history of myocardial infarction, transient ischemic attack, congestive heart failure â‰¥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.\n\nMajor surgery (as defined by the investigator) within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery.\n\nPositive for HIV",
      "Contacts": "Site PI:\nErica Tsang \nErica.tsang@uhn.ca\n\nCoordinator:\nMary (Lan) Wei\nmarylan.wei@uhn.ca\nPager: 416-715-0289\nPhone: 416-946-4501 ext. 3048",
      "NCT number": "NCT06060405",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Resectable",
      "Trial Name": "GO44479/ROCHE (Vaccine Study)\n\n",
      "Full title": "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC",
      "Additional notes": "Fresh tissue collection-prescreening. ",
      "Tissue Requirements": "Tissue collected at surgery for adjuvant vaccine manufacture (must consent for the fresh tissue collection at surgery before the surgery).",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm 1: autogene cevumeran+Atezo+mFOLFIRINOX  \n\nArm 2: mFOLFIRINOX ",
      "Eligibility ": "Inclusion: \nTNM Staging per AJCC: T1-T3, N0-N2, and M0 \nHistologically confirmed diagnosis of PDAC (HOP).\n- adenosquamous carcinoma of the pancreas are eligible for the study.\n- IPMN associated PDAC are NOT eligible for the study.\nInterval of between 6 and 12 weeks since resection of PDAC\nExclusion: \nPrior adjuvant, neoadjuvant, or induction treatment for pancreatic cancer\nKnown complete dihydropyrimidine dehydrogenase (DPD) deficiency \nPositive HIV at screening\nAbsence of spleen (due to splenectomy, splenic injury/infarction, or functional asplenia)\nDistal pancreatectomy with splenectomy is exclusionary.\nPreexisting neuropathy\nSignificant cardiovascular disease\nActive or history of autoimmune disease or immune deficiency\nHistory of malignancy within 5 years prior to screening, with the exception of the\ncancer under investigation in this study and malignancies with a negligible risk of\nmetastasis or death",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nCoordinator:\nGuillaume Cheung\nguillaume.cheung@uhn.ca\nTel: 416-946-4501 ext. 4727",
      "NCT number": "NCT05968326",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Locally Advanced Unresectable",
      "Trial Name": "ABLATE (radiation)\n\n",
      "Full title": "Ablative radiation therapy with high dose geometric Boost for Locally Advanced pancreatic cancer patients following Treatment response Evaluation of standard of care induction chemotherapy (ABLATE): a phase II clinical trial",
      "Additional notes": "Unresectable PDAC on 1L. chemotherapy >16 weeks without progression. ",
      "Tissue Requirements": "Pre-radiation biopsy optional for WGTS, PDO generation and TME studies.\nUp to 5 cores.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Ablative high dose RT: \n    50Gy/5Fx every other day for 2 weeks (UHN) or \n    67.5Gy/15Fx once a day for 3 weeks  or \n    75Gy/25Fx once a day for 5 weeks ",
      "Eligibility ": "Inclusion: \nPancreatic tumour <8.0 cm in greatest axial dimension - final determination  will be based upon satisfying the radiation normal tissue constraints.\nLife expectancy > 6 months\nPrior 1L chemotherapy for at least 16 weeks without clinical or radiographic progression\nExclusion: \nMetastatic disease at the time of registration\nPrior RT to the upper abdomen region that would result in overlap of RT volume\nCurrently on anti-cancer treatment including chemotherapy.",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": "NCT06453486",
      "Study status": "Active",
      "Schema image": "NCT06453486.png"
    },
    {
      "Disease Setting": "Locally Advanced Unresectable",
      "Trial Name": "NASC-009/NCI 10464\n\n",
      "Full title": "A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer",
      "Additional notes": "Unresectable PDAC on 1L. chemotherapy > 16 weeks without progression. ",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Cycle 1: Olaparib BID + Durvalumab C1D1 \n\nCycle 2: Olaparib + Durva + RT (39Gy in 15Fx starting C2D1) \n\nCycle 3 onwards: Olaparib + Durva q4w \n ",
      "Eligibility ": "Inclusion: \nhave had prior 1L chemotherapy for this cancer for at least 16 weeks without clinical, biochemical, or radiologic progression\nBody weight > 30 kg.\nLife expectancy >= 16 weeks.\nWilling to provide archived tissue, if available, from a previous biopsy\nExclusion:\nHad prior upper abdominal radiotherapy prior to entering the study.\nMajor surgical procedure within 28 days prior to enrollment.\nPatients who are receiving any other investigational agents.\nMust not have germline BRCA1 or BRCA2 mutation.",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinator:\nNicole De Pinto\nNicole.DePinto@unityhealth.to\n416-946-4501 ext. 3132",
      "NCT number": "NCT05411094",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1L Metastatic",
      "Trial Name": "CLARITY-PanTumour01\n\n",
      "Full title": "A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2",
      "Additional notes": "Neoadjuvant/adjuvant chemo allowed if progressed \nâ‰¥ 6 months since last dose.\n\nOn hold.",
      "Tissue Requirements": "Pre-screen: needs archival ( â‰¤ 24 months) or fresh tissue ",
      "Biomarker/unselected": "CLDN18.2",
      "Trial Intervention/Arms": "Arm1: AZD0901 in combination with 5FU/leucovorin and Irinotecan or nanoliposomal Irinotecan  \n\nArm2 (CLOSED): AZD0901 combination with Gemcitabine ",
      "Eligibility ": "Inclusion: \nCLDN18.2 positive\nat least one measurable lesion according to RECIST v1.1.\nLife expectancy of â‰¥ 12 weeks.\nExclusion:\nUnstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.\nClinically significant ascites that require drainage.\nHistory of another primary malignancy.",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca\n\nCoordinator (Pre-screen):  \nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757\n\nCoordinator (Screen): \nGuillaume Cheung\nguillaume.cheung@uhn.ca\nTel: 416-946-4501 ext. 4727",
      "NCT number": "NCT06219941",
      "Study status": "Not Recruiting",
      "Schema image": null
    },
    {
      "Disease Setting": "1L Metastatic",
      "Trial Name": "20230223 (AMG193) - MTAP Deletion\n",
      "Full title": "A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion",
      "Additional notes": "MTAP deletion, NGS pre-screening through Foundation Medicine included in study. ",
      "Tissue Requirements": "Pre-screen: needs archival ( â‰¤ 24 months) or fresh tissue",
      "Biomarker/unselected": "MTAP",
      "Trial Intervention/Arms": "AMG 193 alone or in combination with mFOLFIRINOX or with Gemcitabine and Nab-paclitaxel \n\nActive arm: AMG 193 + mFFX",
      "Eligibility ": "Inclusion:\nECOG 0-1 \nTumor tissue (FFPE sample) or an archival block (16 slides) must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before dosing.\nHomozygous MTAP-deletion\nDisease measurable as defined by RECIST v1.1.\nExclusion:\nPrior systemic therapy for advanced or unresectable (locally advanced) adenocarcinoma of the pancreas.\nPrior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\nRadiation therapy within 28 days of first dose.\n",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinators:\nOchir Gansukh\n416-946-4501 ext. 4551\nochir.gansukh@uhn.ca \n\nMaggie Hildebrand \nMaggie.Hildebrand@uhn.ca",
      "NCT number": "NCT06360354",
      "Study status": "Not Recruiting",
      "Schema image": null
    },
    {
      "Disease Setting": "1L Metastatic",
      "Trial Name": "PEGASUS (Glucose Monitoring)\n\n",
      "Full title": "Pancreatic Cancer Glucose Assessment and Regulation Study",
      "Additional notes": "Metastatic PDAC to start 1L. FOLFIRINOX, no prior diabetes diagnosis\nHbA1C < 6.5% ",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Continuous glucose monitor (CGM) for first 2 months of mFFX \n\nArm 1: Intensive glucose intervention with endocrinologist directed glycemic management, with target glucose levels between 4-10 mmol/L \n\nArm 2: Standard of care glucose intervention with intervention only if glucose level >15 mmol/L (Blinded to CGM results) ",
      "Eligibility ": "\nExclusion:\nAbsence of distant or lymph node metastases. Participants with borderline resectable or locally advanced PDAC are not eligible.\nReceived prior systemic therapy (chemotherapy or any other anti-cancer agent) for treatment of metastatic PDAC\nKnown diagnosis of type I diabetes where strict glucose control and close Endocrinology follow-up is already indicated.\nKnown diagnosis of type II diabetes and already followed by Endocrinologist.",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": "NCT05132244",
      "Study status": "Not Recruiting",
      "Schema image": "NCT05132244.png"
    },
    {
      "Disease Setting": "2L Metastatic+",
      "Trial Name": "OZM-114\n\n",
      "Full title": "Phase 1b Expansion Study of CX-5461 In Patients With Solid Tumors and BRCA2 and/or PALB2 mutation",
      "Additional notes": null,
      "Tissue Requirements": "Tumor biopsy at screening and at the time of disease progression.\nBlood collected at screening, Day 1 and Day 8 of cycles 1 and 2 (each cycle is 28 days), every 8 weeks after cycle 2, and at the time of study discontinuation.",
      "Biomarker/unselected": "BRCA2/PALB2",
      "Trial Intervention/Arms": "Phase 1b Expansion Study of CX-5461 In Patients with Solid Tumors and BRCA2 and/or PALB2 mutation ",
      "Eligibility ": "Inclusion: \nHistologically confirmed pancreatic, ovarian, prostate or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation \nMeasurable disease as per RECIST 1.1.\nExclusion:\nPatients with malignant bowel obstruction.\nUnresolved toxicity > CTCAE grade 1 from previous anti-cancer therapy \nTreatment with an investigational (non-registered - other than PARP inhibitor) agent within 30 days and treatment with PARP inhibitor within 14 days prior to the first dose of study medication\nNo concurrent systemic anti-cancer therapy, biological therapy or other novel agent is to be permitted. ",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nCoordinator:\nNicole De Pinto\nNicole.DePinto@unityhealth.to\n416-946-4501 ext. 3132",
      "NCT number": "NCT04890613",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2L Metastatic+",
      "Trial Name": "ADOPT\n\n\n",
      "Full title": "ADOPT: ADaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer, A Prospective Single-Arm Phase II Trial",
      "Additional notes": null,
      "Tissue Requirements": "Fresh tumour biopsy optional at screening for WGTS + PDO generation.\nUp to 6 cores. ",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "PDO-directed therapy",
      "Eligibility ": "Inclusion: \nAdvanced, inoperable PDAC\nStable disease or partial response to FOLFIRINOX after â‰¥4 months (Cohort B)\nDisease progression post-SOC (Cohort A)\nNo max prior treatment lines; recurrence within 6 months of adjuvant-intent chemo eligible\nMust have a Patient Derived Organoid (PDO) showing sensitivity to HC Marketed drug(s)\nExclusion:\nPatients concurrently receiving any other anti-cancer therapy\nPatients with ongoing toxicity â‰¥ CTCAE grade 2; ongoing\nperipheral neuropathy of â‰¥ CTCAE grade 3.\nPatients with a prior or concurrent malignancy whose natural\nhistory or treatment has the potential to interfere with the\nsafety or efficacy assessment of the investigational regimen.",
      "Contacts": "Site PI:\nRobert Grant\nrobert.grant@uhn.ca\n\nCoordinator:\nMary (Lan) Wei\nmarylan.wei@uhn.ca\nPager: 416-715-0289\nPhone: 416-946-4501 ext. 3048",
      "NCT number": "NCT06813079",
      "Study status": "Active",
      "Schema image": "NCT06813079.png"
    },
    {
      "Disease Setting": "2L Metastatic+",
      "Trial Name": "BOLD-100-001\n\n \n\n",
      "Full title": "A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours",
      "Additional notes": "To assess the safety, tolerability and MTD of SOC combination chemotherapy + BOLD-100 in advanced solid tumours",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm VII: dose expansion - randomized 1:1:1 open label to 500 mg/m2 or 625 mg/m2 BOLD-100 in combination with FOLFOX or FOLFOX alone \n\nBOLD-100: IV ruthenium-based small molecule decreasing GRP78 in tumor cells",
      "Eligibility ": "Inclusion: \nHistologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and have measurable disease according to RECIST v1.1 (at least one measurable lesion)\nARM VII --> subjects must have received only 1 prior line of therapy but remain naive to oxaliplatin prior to enrollment\nExclusion: \nMSH-H tumours; concurrent monoclonal antibody therapy: anti-EGFR or anti-VEGF ",
      "Contacts": "Site PI:\nElena Elimova\nelena.elimova@uhn.ca\n\nNurse: \nDowon Choi/Sarah Eng\n\nCDC: \nDivakar Harihar Kanpure",
      "NCT number": "NCT04421820",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2L Metastatic+",
      "Trial Name": "Platinum-Can\n\n\n",
      "Full title": "Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma",
      "Additional notes": null,
      "Tissue Requirements": "Archival tumour tissue unstained slides.",
      "Biomarker/unselected": "BRCA1/2 or PALB2",
      "Trial Intervention/Arms": "NABPLAGEM VS. nab-paclitaxel and gemcitabine\n",
      "Eligibility ": "Inclusion: \nECOG 0-2 \nHistologic documentation of metastatic pancreatic adenocarcinoma, adenosquamous carcinoma, carcinoma or acinar carcinoma\n\nPathogenic BRCA1/2 or PALB2 mutation (somatic or germline)\n \nExclusion:\nNo prior Cisplatin",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinator:\nDowon Choi\nDowon.Choi@uhn.ca\nPhone: 416-946-4501 x 4713",
      "NCT number": "NCT06783140",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "OPCS Registry\n",
      "Full title": "Ontario Pancreas Cancer Study: Identifying genetic, environmental, and lifestyle causes of PDAC",
      "Additional notes": "All PDAC patients\nOntario Pancreas Cancer Study: Identifying genetic, environmental, and lifestyle causes of PDAC",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Questionnaire + one-time blood draw",
      "Eligibility ": "All patients diagnosed with PDAC",
      "Contacts": "Coordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "HPB Banking Protocol\n\n",
      "Full title": "HPB Banking Protocol",
      "Additional notes": "All PDAC patients going to surgery who are not enrolled in Prosper-PANC \n\nAdvanced patients who are not eligible for Prosper-PANC but having a biopsy and investigator requests WGTS",
      "Tissue Requirements": "Fresh tumor collection for WGTS Â± organoids",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Fresh tumor collection for WGTS Â± organoids",
      "Eligibility ": "Clinical (presumed) or pathological diagnosis of any HPB malignancy, specifically HCC, PDAC or CCA, including all histological subtypes or mixed histology.\nAssessed and/or treated at UHN.\nAge >18 years.",
      "Contacts": "Coordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "WATCH-PC\n\n",
      "Full title": "Wearable Devices and Remote Toxicity Checks to Predict Health Outcomes in Pancreatic Cancer",
      "Additional notes": "Planned for/receiving  chemotherapy. \nPts. with no email address,  inability to fluently speak and read English and those admitted as an inpatient at enrolment are excluded.",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Weekly questionnaires\nFitBit Smartwatch\nOn any chemotherapy",
      "Eligibility ": "Inclusion:\nDiagnosis of epithelial pancreatic cancer, confirmed with biopsy or suspected based on\nreview of imaging at the multi-disciplinary conference\nPlan for chemotherapy as part of treatment plan or ongoing treatment\nExclusion: \nLack of an email address\nInability to fluently speak and read English, given the questionnaires will only be\ndeveloped in English at first because of resource constraints\nInability or unwillingness to adhere to the study procedures, at the discretion of the\ninvestigator\nAdmitted as an inpatient at enrolment",
      "Contacts": "Site PI:\nRobert Grant\nrobert.grant@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "2L Only Metastatic",
      "Trial Name": "GSK223675",
      "Full title": "A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.",
      "Additional notes": "Cohort B = PDAC (2L only) - ON PAUSE since 04-Feb-2026.",
      "Tissue Requirements": "Fresh core biopsy (if not feasible, archival tumor tissue, FFPE block (preferred), slides from the most recent biopsy is acceptable).",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Cohort B (PDAC):\nPart 1B: Signal Seeking\nâ€¢ GSK'227 10 mg/kg Q3W\nPart 1B: Optional Extension\nâ€¢ GSK'227 â‰¤ 10 mg/kg Q3W and/or â‰¤ 6 mg/kg Q2W",
      "Eligibility ": "Inclusion criteria: \nâ€¢ Histologically or cytologically confirmed unresectable, LAPDAC or mPDAC.\nâ€¢ Must have received 1 and no more than 1 line of therapy for advanced PDAC, with documented progression (PD on neoadjuvant or adjuvant chemotherapy during treatment or within 6 months of EOT are eligible).\nâ€¢ At least 1 target lesion per RECIST 1.1.\nExclusion criteria: \nâ€¢ Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinoma.\nâ€¢ Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent before first dose of study intervention.\nâ€¢ Has received immunosuppressive agents within 30 days prior to first dose of study intervention.\nâ€¢ Has received any prior therapy with an ADC with a TOPO1-inhibitor payload.\nâ€¢ Has serious or poorly controlled hypertension.",
      "Contacts": "Site PI:\nEric Chen\neric.chen@uhn.ca\n416-946-4501",
      "NCT number": "NCT06885034",
      "Study status": "Not Recruiting",
      "Schema image": "NCT06885034.png"
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "Debio 0123-106",
      "Full title": "Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)",
      "Additional notes": "This is a Phase 1/1b, multi-center, open-label study to evaluate the safety, tolerability, PK,\npharmacodynamics, and preliminary efficacy of lunresertib in combination with Debio 0123, a WEE1 kinase inhibitor. The module will be conducted in 2 parts (4a and 4b): dose escalation (Module 4a) in patients with advanced solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A.\n\nThe study is no longer testing combination of lunresertib and RP-3500 on participants. ",
      "Tissue Requirements": "Archived tumor tissue sample available or lesion that can be safely biopsied if the archival sample is not available. There are no specific requirements for tissue type, but sample needs to have 30% tumour content. Archival sample are to be prepared into 20 slides for IHC, FISH, and DNA/RNA extraction. \n\nPatients who do not have archival sample and biopsy collection are not feasible due to safety reason are still possible to be screen for the study after consultation with study Sponsor. ",
      "Biomarker/unselected": "One of: CCNE1 amplification; FBXW7 deleterious mutations, or PPP2R1A deleterious mutations.",
      "Trial Intervention/Arms": "Patient will be assign to only one dosing schedule - lunresertib in combination with Debio 0123 on the 3 days on/4 days off dosing for two weeks, followed by a week break (2 week on/1 week off). Dosage of lunresertib and Debio0123 may vary.",
      "Eligibility ": "Inclusion Criteria:\n- Male or female and â‰¥12 years-of-age at the time of signature of the ICF.\n- ECOG Performance Status score of 0 or 1. Lansky performance status â‰¥50 for patients â‰¤16 years of age\n- Patients are eligible if, in the opinion of the Investigator, the patient is not a candidate for,\nor would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or if the patient declines standard-of-care therapy. Documented counselling by the center Investigator on benefits/risks of standard-of-care therapy is required for enrolled patients who decline standard-of-care therapy.\n- Measurable disease as per RECIST v1.1.\n- Ability to swallow and retain oral tablets and capsules whole and intact.\n- Hemoglobin â‰¥10.0 g/dL except if anemia is due to potentially reversible and manageable etiology (e.g. bleeding from tumor lesion)\n- Creatinine clearance â‰¥60 mL/min calculated using Cockcroft-Gault equation or measured by 24-hour urine collection. For patients 12 to 17 years of age, renal function should be calculated using Cockcroft-Gault or institutional standard, including institutional formula specific for this age group.\n\nExclusion Criteria:\n- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 halflives,\nand monoclonal antibodies given within 28 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.\n- Presence of other known second malignancy with the exception of any cancer that has been in complete remission for â‰¥ 2 years or completely resected squamous and basal cell carcinomas of the skin.\n- Prior therapy with a PKMYT1 or WEE1 inhibitor.\n- Patients who are unable to swallow oral tablets and capsules whole and intact\n- Clinically significant gastrointestinal abnormality that would affect the absorption of drugs, such as malabsorption syndrome, major resection of the small bowel, total gastrectomy, or inflammatory bowel disease.\n- Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of study drug.\n- Uncontrolled, symptomatic brain metastases.\n- Uncontrolled hypertension (systolic blood pressure â‰¥160 mmHg; diastolic blood pressure â‰¥100 mmHg) despite adequate treatment prior to first dose of study drug.\n- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.\n- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).\n- Mean resting QT interval corrected for heart rate (QTc) interval using the Fridericia formula (QTcF) >450 msec (as calculated per institutional standards) obtained from 3 ECGs â‰¥1 minute apart at study entry.\n- Current treatment with medications that are well-known to prolong the QT interval or with known risk of TdP (Appendix 2). If patients are on these medications, a wash-out period of at least 5 half-lives is needed prior to receiving the treatment.\n- Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccine.",
      "Contacts": "PI: Dr. Stephanie Lheureux\n416-946-2818\nStephanie.Lheureux@uhn.ca\nStudy Coordinator: Vivian Feng\nvivian.feng2@uhn.ca",
      "NCT number": "NCT04855656",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "1L Metastatic",
      "Trial Name": "CA240-0030",
      "Full title": "A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion",
      "Additional notes": "This Phase 2/3 study will evaluate the safety and efficacy of BMS-986504 in combination with nab-p/gem as first-line therapy in previously untreated participants with metastatic PDAC with homozygous MTAP deletion",
      "Tissue Requirements": "Fresh tumor tissue or archival tissue that's obtained within 5 years prior to randomization must be submitted during pre-screening. Eligibility is based on evidence of homozygous MTAP deletion or MTAP loss detected in tumor tissue using Sponsor-provided central test or a Sponsor pre-approved local test. Turnaround time for central FMI testing is 14 calendar days. If participants receive up to 1 cycle of nab-p/gem prior to randomization, tumor tissue must be collected prior to starting nab-p/gem. For fresh tumor tissue, collect 3 research cores.",
      "Biomarker/unselected": "Homozygous MTAP deletion or MTAP loss",
      "Trial Intervention/Arms": "Phase 2:\nArm A- BMS-986504 400 mg QD + nab-paclitaxel & gemcitabine\nArm B- BMS-986504 600 mg QD + nab-paclitaxel & gemcitabine\nArm C- Placebo 400 mg QD + nab-paclitaxel & gemcitabine\nArm D- Placebo 600 mg QD + nab-paclitaxel & gemcitabine\n \nPhase 3:\nArm E- BMS-986504 RP3D + nab-paclitaxel & gemcitabine\nArm F- Placebo + nab-paclitaxel & gemcitabine",
      "Eligibility ": "Inclusion:\nâ€¢ Histologically or cytologically confirmed diagnosis of metastatic PDAC\nâ€¢ Confirmed MTAP deletion or MTAP loss (pre-screening)\nâ€¢ Must not have received any systemic anticancer treatments in the metastatic setting. May receive up to 1 cycle of nab-p/gem in the metastatic setting but must not have progressed or required discontinuation due to intolerable toxicity. Last dose of initial cycle of nab-p/gem must be administered 14 days prior to randomization.\nâ€¢ May have received prior adjuvant and/or neoadjuvant treatments as long as disease did not progress within 6 months of completion of treatment\nâ€¢ At least one measurable lesion according to RECIST v1.1\nâ€¢ ECOG 0-1\n\nExclusion:\nâ€¢ Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to screening.\nâ€¢ Symptomatic brain metastases\nâ€¢ Known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication\nâ€¢ Significant ascites that requires drainage within 1 month prior to randomization\nâ€¢ Prior treatment with a PRMT5 or MAT2A inhibitor",
      "Contacts": "Site PI:\nDr. Jennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131\n\nStudy Coordinator:\nSerena (Ching) Kao",
      "NCT number": "NCT07076121",
      "Study status": "Active",
      "Schema image": "NCT07076121.png"
    },
    {
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "CAN-PREFER",
      "Full title": "Cancer Analysis Neural Networks for Patient Referenced Explanations of Findings from Expert Reports: A Randomized Control Trial of Patient-Facing, Large Language Model-Generated Summaries of Cancer Genomic Testing.",
      "Additional notes": "A single-center, dual-arm, prospective, randomized study.\nPatients with a current diagnosis of any stage of pancreatic or biliary tract cancer who are undergoing genomic biomarker testing as part of their cancer care.",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm 1: SoC clinical genomic testing reports alone.\nArm 2: SoC genomic testing reports + LLM-generated patient-facing\nreport summaries.\nStudy questionnaire sent when enrolled (resent for the re-test subset)",
      "Eligibility ": "Age >18 years.\nDiagnosis of biliary tract or pancreatic cancer at any stage, confirmed by pathology, radiology or multidisciplinary review.\nUnderwent genomic testing at UHN through the Prosper-PANC Study, HPB Tissue Banking Study or LeGresley Biliary Registry.\nAble to read and understand English.",
      "Contacts": "Site PI:\nRobert Grant\nrobert.grant@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": null,
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "pNET": [
    {
      "Disease Setting": "2L Metastatic+",
      "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
      "Full title": "A Phase 2 Study to Evaluate the Efficacy and Safety of MK-6482 Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET).",
      "Additional notes": null,
      "Tissue Requirements": null,
      "Trial Intervention/Arms": "Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.",
      "Eligibility ": "Inclusion criteria:\nPatients with PNET who have progressed on everolimus or sunitinib. \nHas a life expectancy of at least 3 months.\nExclusion criteria:\nUnable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan.\nHistory of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.\nReceived prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention.",
      "Contacts": "Site PI:\nRaymond Jang\nraymond.jang@uhn.ca",
      "NCT number": "NCT04924075",
      "Study status": "Active",
      "Schema image": null
    },
    {
      "Disease Setting": "Any line",
      "Trial Name": "Debio 0123-106",
      "Full title": "Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)",
      "Additional notes": "This is a Phase 1/1b, multi-center, open-label study to evaluate the safety, tolerability, PK,\npharmacodynamics, and preliminary efficacy of lunresertib in combination with Debio 0123, a WEE1 kinase inhibitor. The module will be conducted in 2 parts (4a and 4b): dose escalation (Module 4a) in patients with advanced solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A.\n\nThe study is no longer testing combination of lunresertib and RP-3500 on participants. ",
      "Tissue Requirements": "Archived tumor tissue sample available or lesion that can be safely biopsied if the archival sample is not available. There are no specific requirements for tissue type, but sample needs to have 30% tumour content. Archival sample are to be prepared into 20 slides for IHC, FISH, and DNA/RNA extraction. \n\nPatients who do not have archival sample and biopsy collection are not feasible due to safety reason are still possible to be screen for the study after consultation with study Sponsor. ",
      "Trial Intervention/Arms": "Patient will be assign to only one dosing schedule - lunresertib in combination with Debio 0123 on the 3 days on/4 days off dosing for two weeks, followed by a week break (2 week on/1 week off). Dosage of lunresertib and Debio0123 may vary.",
      "Eligibility ": "Inclusion Criteria:\n- Male or female and â‰¥12 years-of-age at the time of signature of the ICF.\n- ECOG Performance Status score of 0 or 1. Lansky performance status â‰¥50 for patients â‰¤16 years of age\n- Patients are eligible if, in the opinion of the Investigator, the patient is not a candidate for,\nor would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or if the patient declines standard-of-care therapy. Documented counselling by the center Investigator on benefits/risks of standard-of-care therapy is required for enrolled patients who decline standard-of-care therapy.\n- Measurable disease as per RECIST v1.1.\n- Ability to swallow and retain oral tablets and capsules whole and intact.\n- Hemoglobin â‰¥10.0 g/dL except if anemia is due to potentially reversible and manageable etiology (e.g. bleeding from tumor lesion)\n- Creatinine clearance â‰¥60 mL/min calculated using Cockcroft-Gault equation or measured by 24-hour urine collection. For patients 12 to 17 years of age, renal function should be calculated using Cockcroft-Gault or institutional standard, including institutional formula specific for this age group.\n\nExclusion Criteria:\n- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 halflives,\nand monoclonal antibodies given within 28 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.\n- Presence of other known second malignancy with the exception of any cancer that has been in complete remission for â‰¥ 2 years or completely resected squamous and basal cell carcinomas of the skin.\n- Prior therapy with a PKMYT1 or WEE1 inhibitor.\n- Patients who are unable to swallow oral tablets and capsules whole and intact\n- Clinically significant gastrointestinal abnormality that would affect the absorption of drugs, such as malabsorption syndrome, major resection of the small bowel, total gastrectomy, or inflammatory bowel disease.\n- Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of study drug.\n- Uncontrolled, symptomatic brain metastases.\n- Uncontrolled hypertension (systolic blood pressure â‰¥160 mmHg; diastolic blood pressure â‰¥100 mmHg) despite adequate treatment prior to first dose of study drug.\n- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.\n- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).\n- Mean resting QT interval corrected for heart rate (QTc) interval using the Fridericia formula (QTcF) >450 msec (as calculated per institutional standards) obtained from 3 ECGs â‰¥1 minute apart at study entry.\n- Current treatment with medications that are well-known to prolong the QT interval or with known risk of TdP (Appendix 2). If patients are on these medications, a wash-out period of at least 5 half-lives is needed prior to receiving the treatment.\n- Immunization with live or live-attenuated vaccine within 28 days prior to study inclusion or planned injection of live or live-attenuated vaccine.",
      "Contacts": "PI: Dr. Stephanie Lheureux\n416-946-2818\nStephanie.Lheureux@uhn.ca\nStudy Coordinator: Vivian Feng\nvivian.feng2@uhn.ca",
      "NCT number": "NCT04855656",
      "Study status": "Active",
      "Schema image": null
    }
  ],
  "Preactivation": [
    {
      "Organ group": "PDAC",
      "Disease Setting": "1L Metastatic",
      "Trial Name": "RIVER-mPDAC",
      "Full title": "Research Investigation of ponsegromab in cancer cachexia-metastatic Pancreatic Ductal Adenocarcinoma",
      "Additional notes": "Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.",
      "Tissue Requirements": "Archival tumor FFPE biopsy block or unstained freshly cut paraffin sections\nof tumor specimen collected within 6 months of enrollment.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Ponsegromab Doubleblind Treatment 200 mg Q4W\nPonsegromab Doubleblind Treatment 400 mg Q4W\nPlacebo Double-blind Treatment Q4W",
      "Eligibility ": "Inclusion:\nActive diagnosis of metastatic pancreatic ductal adenocarcinoma\nCachexia defined by Fearon criteria of weight loss\nCompleted 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy\nECOG PS â‰¤1 with life expectancy of at least 4 months\nExclusion:\nCurrent active reversible causes of decreased food intake\nCachexia caused by other reasons\nHistory of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody\nNeuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases\nRenal disease requiring dialysis or eGFR <30 mL/min/1.73m2",
      "Contacts": null,
      "NCT number": "NCT06989437",
      "Schema image": null
    }
  ],
  "Closed": [
    {
      "Organ group": "PDAC",
      "Disease Setting": "1L Metastatic",
      "Trial Name": "PRISM-1\n\n\n\n",
      "Full title": "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Treatment NaÃ¯ve Metastatic Pancreatic Ductal Adenocarcinoma",
      "Additional notes": "Previously untreated mPDAC\nNeo/Adj permitted if given >12m before randomization.",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Arm A (Experimental Arm)\nDoses and administration of quemliclustat, NP, and Gem will be administered using a 28-day cycle\n\nArm B (Comparator Arm)\nDoses and administration of placebo, NP, and Gem will be administered using a 28-day cycle",
      "Eligibility ": "Inclusion:\nNo prior treatment for metastatic PDAC\nPrior neoadjuvant/adjuvant therapy allowed if >12 months ago\nPrior palliative radiation allowed if completed â‰¥2 weeks before randomization and AEs resolved to â‰¤ Grade 1\nBiliary stent/tube allowed if no active obstruction and AEs â‰¤ Grade 1\nâ‰¥1 measurable lesion by CT/MRI (RECIST v1.1)\nAdequate organ, marrow, and coagulation function\nExclusion:\nPreviously treated for locally advanced, unresectable PDAC.\nHistory of brain metastases or leptomeningeal metastases.\nPrior treatment with a CD73 antagonist or inhibitor.",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinator:\nOchir Gansukh\n416-946-4501 ext. 4551\nochir.gansukh@uhn.ca ",
      "NCT number": "NCT06608927",
      "Schema image": null
    },
    {
      "Organ group": "CCA",
      "Disease Setting": "Adjuvant",
      "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
      "Full title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)",
      "Additional notes": "UHN has reached target enrollment. Additional slots may be available - request from Sponsor",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "A: rilvegostomig + SOC\nB: placebo + SOC",
      "Eligibility ": "R0/R1 resection, within 12 weeks\nNo ampullary/NET",
      "Contacts": "Site PI:\nJennifer Knox\njennifer.knox@uhn.ca\n416-946-2000 x 5131",
      "NCT number": "NCT06109779",
      "Schema image": "NCT06109779.png"
    },
    {
      "Organ group": "PDAC",
      "Disease Setting": "Resectable",
      "Trial Name": "Prosper-PANC Cohort 1\n",
      "Full title": "Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial",
      "Additional notes": "Cohort 1: upfront surgery (neoadj.  chemo excluded; immunotherapy permitted).\nCohort 2: minimum of 4 to 6 cores must be safely obtained from single lesion biopsy.",
      "Tissue Requirements": "Fresh tissue collection (6 quality cores or 4 pieces of resection tissue) for WGTS + organoids.\nSerial blood draws for ctDNA at baseline, 8W post-surgery, Post-adjuvant completion and at end of study.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Standard of care intervention",
      "Eligibility ": "Inclusion: \nUpfront resectable\nLife expectancy of â‰¥ 6 months\nMust be suitable for systemic therapy\nExclusion: \nHistologies excluded: colloid, high grade neuroendocrine\nPatients receiving neoadjuvant chemotherapy (neoadjuvant immunotherapy is permitted)",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": "NCT05927298",
      "Schema image": "NCT05927298.png"
    },
    {
      "Organ group": "PDAC",
      "Disease Setting": "Any Line Advanced",
      "Trial Name": "Prosper-PANC Cohort 2\n\n",
      "Full title": "Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial",
      "Additional notes": "Unresectable, locally advanced and metastatic PDAC \n\nAt initial diagnosis or at progression â€“ goal is to look for actionable mutations",
      "Tissue Requirements": "Fresh tissue collection (6 quality cores or 4 pieces of resection tissue) for WGTS + organoids.\nSerial blood draws wk 2, 4, 8 and q8 for ctDNA. Bloods also collected at progression and q12w for follow-up. For matched cohort, bloods are collected at baseline, q8w on matched-treatment, progression and q12w on follow-up.",
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Standard of care intervention",
      "Eligibility ": "Inclusion: \nAll stages are eligible including locally advanced unresectable, first-line metastatic, second-line (or beyond) metastatic\nSingle lesion is to be biopsied: a minimum of 4 to 6 x 18 Gauge (G) good quality tumour cores must be safely obtainable.\nExclusion:\nWithout a tumour lesion amenable to biopsy or with tumour lesions that are not safe for sampling a minimum of 4 to 6 x 18G good quality tumour cores\nPatients who are not fit enough to undergo a tumour biopsy ",
      "Contacts": "Site PI:\nErica Tsang\nErica.Tsang@uhn.ca\n\nCoordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": "NCT05927298",
      "Schema image": "NCT05927298.png"
    },
    {
      "Organ group": "PDAC",
      "Disease Setting": "Non-Therapeutic",
      "Trial Name": "NUANCE\n\n",
      "Full title": "Optimizing Nutrition in patients with PDAC on chemo",
      "Additional notes": "Optimizing Nutrition in patients with PDAC on chemo ",
      "Tissue Requirements": null,
      "Biomarker/unselected": null,
      "Trial Intervention/Arms": "Weekly / monthly calls with Dietician, Clinical Nurse Specialist and Social Worker \n\nQOL questionnaires at BL, 2 months and 6 months ",
      "Eligibility ": "Patients diagnosed with PDAC on chemotherapy",
      "Contacts": "Coordinators:\nRachel Ding: \nrachel.ding@uhn.ca\n437-990-4238\n\nDorian Facey: \ndorian.facey@uhn.ca\n437-779-7757",
      "NCT number": null,
      "Schema image": null
    }
  ],
  "Dropdown Menus": [
    {
      "Study status": "Active"
    },
    {
      "Study status": "Not Recruiting"
    }
  ],
  "Biomarkers": [
    {
      "Biomarker": "HER2 "
    },
    {
      "Biomarker": "CLDN18.2"
    },
    {
      "Biomarker": "HER2 and PDL1"
    },
    {
      "Biomarker": "HER-2 on IHC"
    },
    {
      "Biomarker": "IDH1"
    },
    {
      "Biomarker": "Claudin18.2"
    },
    {
      "Biomarker": "MTAP"
    }
  ],
  "Changes": {
    "PDAC": [
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-09-03T16:13:58"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-09-08T13:00:39"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-09-15T16:50:23"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "ABLATE (radiation)\n\n",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "CLARITY-PanTumour01 - Claudin 18.2\n\n",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "20230223 (AMG193) - MTAP Deletion\n\n",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "PEGASUS (Glucose Monitoring)\n\n",
        "change": "modified",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "PRISM-1 (NOT RECRUITING)\n\n\n\n",
        "change": "added",
        "timestamp": "2025-09-15T17:19:28"
      },
      {
        "Trial Name": "CLARITY-PanTumour01 - Claudin 18.2\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T09:56:09"
      },
      {
        "Trial Name": "20230223 (AMG193) - MTAP Deletion\n(NOT RECRUITING)\n",
        "change": "added",
        "timestamp": "2025-09-17T11:07:24"
      },
      {
        "Trial Name": "20230223 (AMG193) - MTAP Deletion\n (NOT RECRUITING)\n",
        "change": "added",
        "timestamp": "2025-09-17T11:28:06"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "ABLATE (radiation)\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "ADOPT\n\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "Platinum-Can\n\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "NUANCE\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "OPCS Registry\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "HPB Banking Protocol\n\n",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "OZM-114\n\n",
        "change": "modified",
        "timestamp": "2025-09-18T15:34:07"
      },
      {
        "Trial Name": "Platinum-Can\n\n\n",
        "change": "modified",
        "timestamp": "2025-09-18T15:34:07"
      },
      {
        "Trial Name": "RIVER-mPDAC (Pre-activation)",
        "change": "added",
        "timestamp": "2025-09-18T15:34:07"
      },
      {
        "Trial Name": "20230223 (AMG193) - MTAP Deletion\n",
        "change": "added",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "PRISM-1\n\n\n\n",
        "change": "added",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "RIVER-mPDAC (Pre-activation)",
        "change": "modified",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "ABLATE (radiation)\n\n",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "PEGASUS (Glucose Monitoring)\n\n",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "ADOPT\n\n\n",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "CLARITY-PanTumour01 - Claudin 18.2\n\n",
        "change": "modified",
        "timestamp": "2025-09-29T08:43:23"
      },
      {
        "Trial Name": "CLARITY-PanTumour01 - Claudin 18.2 - GnP arm open\n\n",
        "change": "added",
        "timestamp": "2025-10-20T10:16:48"
      },
      {
        "Trial Name": "CLARITY-PanTumour01 - Claudin 18.2 \n\n",
        "change": "added",
        "timestamp": "2025-10-20T10:19:01"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-10-20T10:36:03"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-10-20T10:42:45"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2025-10-21T15:20:12"
      },
      {
        "Trial Name": "CLARITY-PanTumour01\n\n",
        "change": "added",
        "timestamp": "2025-10-23T10:00:03"
      },
      {
        "Trial Name": "CLARITY-PanTumour01\n\n",
        "change": "modified",
        "timestamp": "2025-10-28T12:24:51"
      },
      {
        "Trial Name": "GO44479/ROCHE (Vaccine Study)\n\n",
        "change": "modified",
        "timestamp": "2025-11-04T15:19:21"
      },
      {
        "Trial Name": "NUANCE\n\n",
        "change": "modified",
        "timestamp": "2025-11-05T14:33:15"
      },
      {
        "Trial Name": "PEGASUS (Glucose Monitoring)\n\n",
        "change": "modified",
        "timestamp": "2025-11-07T12:51:14"
      },
      {
        "Trial Name": "BOLD-100-001\n\n \n\n",
        "change": "modified",
        "timestamp": "2025-11-14T11:30:18"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "modified",
        "timestamp": "2025-11-17T15:04:54"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "modified",
        "timestamp": "2025-11-17T15:04:54"
      },
      {
        "Trial Name": "OZM-114\n\n",
        "change": "modified",
        "timestamp": "2025-11-17T15:04:54"
      },
      {
        "Trial Name": "WATCH-PC\n\n",
        "change": "modified",
        "timestamp": "2025-11-17T15:18:13"
      },
      {
        "Trial Name": "GO44479/ROCHE (Vaccine Study)\n\n",
        "change": "modified",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "CLARITY-PanTumour01\n\n",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "modified",
        "timestamp": "2025-12-17T12:17:43"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "modified",
        "timestamp": "2025-12-17T12:17:43"
      },
      {
        "Trial Name": "GSK223675 (Cohort B only)",
        "change": "added",
        "timestamp": "2026-01-09T12:55:07"
      },
      {
        "Trial Name": "GSK223675",
        "change": "added",
        "timestamp": "2026-01-09T12:58:08"
      },
      {
        "Trial Name": "GSK223675",
        "change": "modified",
        "timestamp": "2026-01-12T10:10:57"
      },
      {
        "Trial Name": "GSK223675",
        "change": "modified",
        "timestamp": "2026-01-12T10:23:42"
      },
      {
        "Trial Name": "GSK223675",
        "change": "modified",
        "timestamp": "2026-01-20T12:29:09"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "added",
        "timestamp": "2026-02-02T13:59:12"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "added",
        "timestamp": "2026-02-03T15:30:22"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "modified",
        "timestamp": "2026-02-04T08:58:08"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "modified",
        "timestamp": "2026-02-04T09:01:34"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "modified",
        "timestamp": "2026-02-04T09:10:03"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "modified",
        "timestamp": "2026-02-04T09:10:47"
      },
      {
        "Trial Name": "DORA (WOO)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GO44479/ROCHE (Vaccine Study)\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ABLATE (radiation)\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "NASC-009/NCI 10464\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CLARITY-PanTumour01\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "20230223 (AMG193) - MTAP Deletion\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "PEGASUS (Glucose Monitoring)\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "OZM-114\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ADOPT\n\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "BOLD-100-001\n\n \n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Platinum-Can\n\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "OPCS Registry\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "HPB Banking Protocol\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "WATCH-PC\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GSK223675",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CA240-0030",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GSK223675",
        "change": "modified",
        "timestamp": "2026-02-04T11:25:25"
      },
      {
        "Trial Name": "CAN-PREFER",
        "change": "added",
        "timestamp": "2026-02-23T13:18:05"
      }
    ],
    "HCC": [
      {
        "Trial Name": "CaboTx\n ",
        "change": "added",
        "timestamp": "2025-09-08T13:47:39"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-09-11T16:43:46"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-11T16:43:46"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-11T17:08:18"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-15T20:36:55"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "added",
        "timestamp": "2025-09-15T20:36:55"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-09-15T20:58:52"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-15T20:58:52"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-09-15T20:58:52"
      },
      {
        "Trial Name": "CaboTx\n ",
        "change": "modified",
        "timestamp": "2025-09-15T20:58:52"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-09-16T14:42:22"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "added",
        "timestamp": "2025-09-16T14:42:22"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2025-09-16T14:42:22"
      },
      {
        "Trial Name": "HE.2 / SLIDE-HCC",
        "change": "added",
        "timestamp": "2025-09-16T14:42:22"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "HE.2 / SLIDE-HCC",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "CaboTx\n ",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "added",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "HE.2",
        "change": "added",
        "timestamp": "2025-09-16T16:58:38"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "HE.2",
        "change": "modified",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2025-09-23T16:09:52"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "HE.2",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "CaboTx\n ",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "HMLTO002",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "HE.2",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "CaboTx\n ",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2025-09-25T17:47:36"
      },
      {
        "Trial Name": "BANTAM-01",
        "change": "added",
        "timestamp": "2025-10-27T07:31:34"
      },
      {
        "Trial Name": "BANTAM-01",
        "change": "modified",
        "timestamp": "2025-10-27T07:33:02"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "BeyondIO",
        "change": "added",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "HE.2",
        "change": "modified",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "SURF-431",
        "change": "added",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "BeyondIO",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "SURF-431",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "BANTAM-01",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "BeyondIO (HMLTO002)",
        "change": "added",
        "timestamp": "2026-02-02T09:49:47"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "added",
        "timestamp": "2026-02-02T09:49:47"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "added",
        "timestamp": "2026-02-02T13:59:12"
      },
      {
        "Trial Name": "NEOTOMA",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "BeyondIO (HMLTO002)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ARTEMIDE HCC01",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "HE.2",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CHS-388-202",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CaboTx\n ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ITER-002-HCC",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "BANTAM-01",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "TYR430-101",
        "change": "modified",
        "timestamp": "2026-02-20T11:08:30"
      }
    ],
    "Gastroesophageal": [
      {
        "Trial Name": "Molecular Characteristics of Gastroesophageal Adenocarcinoma ",
        "change": "modified",
        "timestamp": "2025-09-08T16:32:17"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2025-09-08T16:32:17"
      },
      {
        "Trial Name": "GEAR",
        "change": "added",
        "timestamp": "2025-09-08T16:32:17"
      },
      {
        "Trial Name": "MOCHA",
        "change": "added",
        "timestamp": "2025-09-09T10:28:17"
      },
      {
        "Trial Name": "Destiny-Gastric 003 ",
        "change": "modified",
        "timestamp": "2025-09-09T10:58:55"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-09-09T10:58:55"
      },
      {
        "Trial Name": "ARTEMIDE-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-09-09T10:58:55"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2025-09-09T10:58:55"
      },
      {
        "Trial Name": "Destiny-Gastric 003 ",
        "change": "modified",
        "timestamp": "2025-09-09T11:23:13"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2025-09-09T11:23:13"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-09-09T11:23:13"
      },
      {
        "Trial Name": "GEAR",
        "change": "modified",
        "timestamp": "2025-09-09T11:23:13"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-09-09T11:34:03"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-09-09T11:37:54"
      },
      {
        "Trial Name": "Destiny-Gastric 03 ",
        "change": "added",
        "timestamp": "2025-09-10T17:29:55"
      },
      {
        "Trial Name": "Destiny-Gastric 03 ",
        "change": "modified",
        "timestamp": "2025-09-10T17:39:06"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-09-10T17:39:06"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2025-09-10T17:39:06"
      },
      {
        "Trial Name": "GEAR",
        "change": "modified",
        "timestamp": "2025-09-23T09:20:07"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2025-09-26T13:35:41"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-10-01T09:58:43"
      },
      {
        "Trial Name": "ARTEMIDE-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-10-01T09:58:43"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2025-10-03T14:08:54"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-10-03T14:08:54"
      },
      {
        "Trial Name": "GEAR",
        "change": "modified",
        "timestamp": "2025-10-27T07:31:34"
      },
      {
        "Trial Name": "Destiny-Gastric 03 ",
        "change": "modified",
        "timestamp": "2025-11-14T10:27:58"
      },
      {
        "Trial Name": "Destiny-Gastric 03 ",
        "change": "modified",
        "timestamp": "2025-11-14T10:29:10"
      },
      {
        "Trial Name": "Destiny-Gastric 03 ",
        "change": "modified",
        "timestamp": "2025-11-14T12:22:36"
      },
      {
        "Trial Name": "MOCHA",
        "change": "modified",
        "timestamp": "2025-11-17T13:44:32"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-11-17T13:44:32"
      },
      {
        "Trial Name": "ARTEMIDE-Gastric01 ",
        "change": "modified",
        "timestamp": "2025-11-17T13:44:32"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2025-11-17T13:44:32"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2025-11-18T07:36:49"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "MOCHA",
        "change": "modified",
        "timestamp": "2026-01-12T16:22:00"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2026-01-12T16:22:00"
      },
      {
        "Trial Name": "IRONGOOSE",
        "change": "added",
        "timestamp": "2026-01-12T16:22:00"
      },
      {
        "Trial Name": "DEFEAT",
        "change": "added",
        "timestamp": "2026-01-12T16:22:00"
      },
      {
        "Trial Name": "NEEDS",
        "change": "added",
        "timestamp": "2026-01-12T16:22:00"
      }
    ],
    "CCA": [
      {
        "Trial Name": "ZW25 + SOC vs SOC in Her-2+ BTC",
        "change": "modified",
        "timestamp": "2025-09-10T14:22:59"
      },
      {
        "Trial Name": "Clarity-Pantumor",
        "change": "modified",
        "timestamp": "2025-09-10T14:35:36"
      },
      {
        "Trial Name": "TYR430",
        "change": "added",
        "timestamp": "2025-09-10T14:35:36"
      },
      {
        "Trial Name": "ZW25 + SOC vs SOC in Her-2+ BTC",
        "change": "modified",
        "timestamp": "2025-09-10T16:20:54"
      },
      {
        "Trial Name": "CGT4859 ",
        "change": "modified",
        "timestamp": "2025-09-10T16:20:54"
      },
      {
        "Trial Name": "Clarity-Pantumor",
        "change": "modified",
        "timestamp": "2025-09-16T14:42:22"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302",
        "change": "added",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "TYR430",
        "change": "modified",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": " FOENIX-CCA4",
        "change": "added",
        "timestamp": "2025-09-16T16:57:30"
      },
      {
        "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
        "change": "modified",
        "timestamp": "2025-09-17T11:55:13"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302",
        "change": "modified",
        "timestamp": "2025-09-17T11:55:13"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302 (Sponsor: Jazz pharma)",
        "change": "added",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "ProvIHDe",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "CGT4859 ",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "TYR430",
        "change": "modified",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": " FOENIX-CCA4  (Sponsor: Taiho)",
        "change": "added",
        "timestamp": "2025-09-17T12:54:50"
      },
      {
        "Trial Name": "CGT4859 ",
        "change": "modified",
        "timestamp": "2025-09-24T14:25:19"
      },
      {
        "Trial Name": "TYR430",
        "change": "modified",
        "timestamp": "2025-09-24T14:25:19"
      },
      {
        "Trial Name": "FOENIX-CCA4  (Sponsor: Taiho)\nTAS-120-205",
        "change": "added",
        "timestamp": "2025-09-24T14:25:19"
      },
      {
        "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "Destiny-BTC01",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302 (Sponsor: Jazz pharma)",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "ProvIHDe",
        "change": "modified",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "S095031-210",
        "change": "added",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "S095031-210",
        "change": "modified",
        "timestamp": "2025-10-22T14:37:07"
      },
      {
        "Trial Name": "CLARITY-PanTumour01",
        "change": "added",
        "timestamp": "2025-10-23T09:52:52"
      },
      {
        "Trial Name": "FOENIX-CCA4 \nTAS-120-205",
        "change": "added",
        "timestamp": "2025-11-10T14:23:47"
      },
      {
        "Trial Name": "CLARITY-PanTumour01",
        "change": "modified",
        "timestamp": "2025-11-17T13:44:32"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302 (Sponsor: Jazz pharma)",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "ProvIHDe",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "CGT4859 ",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "S095031-210",
        "change": "modified",
        "timestamp": "2025-11-17T14:49:36"
      },
      {
        "Trial Name": "SURF-431",
        "change": "added",
        "timestamp": "2025-12-15T10:55:14"
      },
      {
        "Trial Name": "CLARITY-PanTumour01",
        "change": "modified",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Destiny-BTC01",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "\nHERIZON-BTC-302 (Sponsor: Jazz pharma)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CLARITY-PanTumour01",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ProvIHDe",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CGT4859 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "SURF-431",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "FOENIX-CCA4 \nTAS-120-205",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "S095031-210",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CAN-PREFER",
        "change": "added",
        "timestamp": "2026-02-23T13:18:05"
      }
    ],
    "Preactivation": [
      {
        "Trial Name": "Research Investigation of ponsegromab in cancer cachexia-metastatic Pancreatic Ductal Adenocarcinoma",
        "change": "added",
        "timestamp": "2025-09-23T17:05:42"
      },
      {
        "Trial Name": "RIVER-mPDAC",
        "change": "added",
        "timestamp": "2025-10-27T07:31:34"
      },
      {
        "Trial Name": "DESTINY-Gastric",
        "change": "added",
        "timestamp": "2026-01-12T16:22:00"
      },
      {
        "Trial Name": "RIVER-mPDAC",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      }
    ],
    "Closed": [
      {
        "Trial Name": "PRISM-1\n\n\n\n",
        "change": "added",
        "timestamp": "2025-09-25T17:35:04"
      },
      {
        "Trial Name": "PRISM-1\n\n\n\n",
        "change": "modified",
        "timestamp": "2025-09-25T18:00:10"
      },
      {
        "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
        "change": "added",
        "timestamp": "2025-12-15T11:34:12"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "added",
        "timestamp": "2026-01-27T14:44:57"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "added",
        "timestamp": "2026-01-27T14:44:57"
      },
      {
        "Trial Name": "NUANCE\n\n",
        "change": "added",
        "timestamp": "2026-01-27T14:44:57"
      },
      {
        "Trial Name": "PRISM-1\n\n\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Rilvegostomig+cape as adjuvant after resection of BTC (Artemide-Biliary)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 1\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Prosper-PANC Cohort 2\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "NUANCE\n\n",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      }
    ],
    "CRC": [
      {
        "Trial Name": "Phase 3, randomized peri-op dostarlimab vs SOC T4N0 or Stage III dMMR/MSI-H Colon Cancer ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "OrigAMI-2 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "CANTOR",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "INTRINSIC",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "BOLD-100-001 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "Phase 3, randomized peri-op dostarlimab vs SOC T4N0 or Stage III dMMR/MSI-H Colon Cancer ",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "OrigAMI-2 ",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "CANTOR",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "INTRINSIC",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "added",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "Battman (CO33)",
        "change": "added",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "INTRINSIC",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "BOLD-100-001 ",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "Battman (CO33)",
        "change": "modified",
        "timestamp": "2026-01-13T14:01:16"
      },
      {
        "Trial Name": "INTRINSIC",
        "change": "modified",
        "timestamp": "2026-01-15T15:01:35"
      },
      {
        "Trial Name": "Battman (CO33)",
        "change": "modified",
        "timestamp": "2026-01-15T15:01:35"
      },
      {
        "Trial Name": "Phase 3, randomized peri-op dostarlimab vs SOC T4N0 or Stage III dMMR/MSI-H Colon Cancer ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "OrigAMI-2 ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "CANTOR",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "INTRINSIC",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "BOLD-100-001 ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "Battman (CO33)",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "added",
        "timestamp": "2026-01-19T16:43:07"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-01-19T16:58:16"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-19T16:58:16"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-19T16:58:16"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T09:37:58"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T10:36:05"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T10:56:57"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-01-20T10:57:34"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T11:03:07"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T11:05:23"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T11:06:04"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-01-20T11:07:05"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-01-20T11:09:21"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-01-20T11:09:44"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-01-20T11:10:42"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:11:13"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:12:08"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T11:13:51"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:14:35"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T11:14:35"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:15:26"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:16:49"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-01-20T11:16:49"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-01-20T11:17:55"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:20:20"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:23:46"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:25:49"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:27:11"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-01-20T11:27:49"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "added",
        "timestamp": "2026-02-02T13:59:12"
      },
      {
        "Trial Name": "GSK219606 (AZUR2)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "61186372COR3001 (ORIGAMI-2)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "D798VC00001 (CANTOR)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "WO42758 (INTRINSIC)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "BOLD-100-001 (TRIO039)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "C4761001 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ONO-4578-10",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "CO.33 (BATTMAN)",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GSK223675 ",
        "change": "modified",
        "timestamp": "2026-02-04T15:31:29"
      },
      {
        "Trial Name": "Phase 1 of NDI-219216 in Patients with Advanced Solid Tumors with MSI-H/dMMR",
        "change": "added",
        "timestamp": "2026-02-20T11:08:30"
      }
    ],
    "GE": [
      {
        "Trial Name": "MOCHA",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "ARTEMIDE-Gastric01 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "TORO ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "GEAR",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "IRONGOOSE",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "DEFEAT",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "NEEDS",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "DESTINY-Gastric03",
        "change": "added",
        "timestamp": "2026-01-15T14:23:11"
      },
      {
        "Trial Name": "AndroMETa-GEA-977",
        "change": "added",
        "timestamp": "2026-01-15T14:23:11"
      },
      {
        "Trial Name": "MOCHA",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Clarity-Gastric01 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "ARTEMIDE-Gastric01 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GA.4 ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "TORO ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "REJOICE-GI01",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "GEAR",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "IRONGOOSE",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "DEFEAT",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "NEEDS",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "DESTINY-Gastric03",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "AndroMETa-GEA-977",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      }
    ],
    "pNET": [
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "added",
        "timestamp": "2026-01-13T11:23:38"
      },
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "modified",
        "timestamp": "2026-01-13T13:24:08"
      },
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "modified",
        "timestamp": "2026-01-15T16:03:49"
      },
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "modified",
        "timestamp": "2026-01-15T16:52:11"
      },
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "modified",
        "timestamp": "2026-01-20T12:09:51"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "added",
        "timestamp": "2026-02-02T13:59:12"
      },
      {
        "Trial Name": "Belzutifan Advanced Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015) ",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      },
      {
        "Trial Name": "Debio 0123-106",
        "change": "modified",
        "timestamp": "2026-02-04T09:41:02"
      }
    ]
  }
}